

st is in DialUnits

? b 410

21jul08 15:14:52 User208760 Session D2961.1  
\$0.55 0.152 DialUnits File1  
\$0.55 Estimated cost File1  
\$0.55 Estimated cost this search  
\$0.55 Estimated total session cost 0.152 DialUnits

File 410:Dialog Comm.-of-Interest Newsletters 2008 /Mar  
(c) 2008 Dialog

Set	Items	Description
-----	-------	-------------

? set hi ;set hi

HIGHLIGHT set on as ''

HIGHLIGHT set on as ''

? begin 5,73,155,399

21jul08 15:14:57 User208760 Session D2961.2  
\$0.00 0.117 DialUnits File410  
\$0.00 Estimated cost File410  
\$0.02 TELNET  
\$0.02 Estimated cost this search  
\$0.57 Estimated total session cost 0.269 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1926-2008/Jul W2  
(c) 2008 The Thomson Corporation

File 73:EMBASE 1974-2008/Jul 18  
(c) 2008 Elsevier B.V.

File 155:MEDLINE(R) 1950-2008/Jul 17  
(c) format only 2008 Dialog

File 399:CA SEARCH(R) 1967-2008/UD=14904  
(c) 2008 American Chemical Society

\*File 399: Use is subject to the terms of your user/customer agreement.  
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

Set	Items	Description
-----	-------	-------------

? s (cd40)(10n)(agonist?) and (cd20 or rituxan or rituximab)

34908	CD40
589238	AGONIST?
698	CD40(10N)AGONIST?
21687	CD20
1876	RITUXAN
20705	RITUXIMAB

S1	15	(CD40)(10N)(AGONIST?) AND (CD20 OR RITUXAN OR RITUXIMAB)
----	----	--

? rd s1

S2	9	RD S1 (unique items)
----	---	----------------------

? t s2/3/all

2/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

18839939 BIOSIS NO.: 200600185334

Humanized anti CD-40 antibody SGN-40 effectively induces cytotoxicity  
against chronic lymphocytic leukemia (CLL) cells through antibody  
mediated cytotoxicity and demonstrates modest biologic evidence of CD40  
activation

AUTHOR: Gowda Aruna C (Reprint); Zhao Xiaobin B; Cheney Carolyn; Mehter  
Najma; Lozanski Gerard; Lin Thomas S; Guster Sara; Drachman J G;

Muthusamy Natarajan; Byrd John C  
AUTHOR ADDRESS: Ohio State Univ, Columbus, OH 43210 USA\*\*USA  
JOURNAL: Blood 106 (11, Part 1): p832A NOV 16 2005 2005  
CONFERENCE/MEETING: 47th Annual Meeting of the  
American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005;  
20051210  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster  
RECORD TYPE: Abstract  
LANGUAGE: English

2/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18618720 BIOSIS NO.: 200510313220  
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal  
antibody, SGN-40  
AUTHOR: Law Che-Leung (Reprint); Gordon Kristine A; Collier John; Klussman  
Kerry; McEarchern Julie A; Cervený Charles G; Mixan Bruce J; Lee Wyne P;  
Lin Zhonghau; Valdez Patricia; Wahl Alan F; Grewal Iqbal S  
AUTHOR ADDRESS: Seattle Genet Inc, 21823 30th Dr SE, Bothell, WA 98021 USA  
\*\*USA  
AUTHOR E-MAIL ADDRESS: claw@seagen.com  
JOURNAL: Cancer Research 65 (18): p8331-8338 SEP 15 2005 2005  
ISSN: 0008-5472  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

2/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18576751 BIOSIS NO.: 200510271251  
A fully human anti-CD40 antagonistic antibody, CHIR-12.12, inhibit the  
proliferation of human B cell non-Hodgkin's lymphoma  
AUTHOR: Weng Wen-Kai (Reprint); Tong Xia; Luqman Mohammad; Levy Ronald  
AUTHOR ADDRESS: Stanford Univ, Sch Med, Stanford, CA 94305 USA\*\*USA  
JOURNAL: Blood 104 (11, Part 1): p896A NOV 16 2004 2004  
CONFERENCE/MEETING: 46th Annual Meeting of the  
American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004;  
20041204  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster  
RECORD TYPE: Abstract  
LANGUAGE: English

2/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18234887 BIOSIS NO.: 200500141952  
Development of a chimeric anti-CD40 monoclonal antibody that synergizes  
with LEA29Y to prolong islet allograft survival  
AUTHOR: Adams Andrew B; Shirasugi Nozomu; Jones Thomas R; Durham Megan M;

Strobert Elizabeth A; Cowan Shannon; Rees Phyllis; Hendrix Rose; Price Karen; Kenyon Norma S; Hagerty David; Townsend Robert; Hollenbaugh Dianne ; Pearson Thomas C (Reprint); Larsen Christian P  
AUTHOR ADDRESS: Dept Surg, Emory Transplant Ctr, Suite 5105, Woodruff Mem Res Bldg, 101 Woodruff Cir, Atlanta, GA, 30332, USA\*\*USA  
AUTHOR E-MAIL ADDRESS: tpearson@emoryhealthcare.org;  
clarsen@emoryhealthcare.org  
JOURNAL: Journal of Immunology 174 (1): p542-550 January 1, 2005 2005  
MEDIUM: print  
ISSN: 0022-1767 \_(ISSN print)  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

2/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

16647704 BIOSIS NO.: 200200241215  
Human anti-CD40 antagonistic antibodies inhibit the proliferation of human B cell non-Hodgkin's lymphoma  
AUTHOR: Weng Wen-Kai (Reprint); Wang Changyu; Chu Keting; Levy Ronald (Reprint)  
AUTHOR ADDRESS: Medicine/Oncology, Stanford University, Stanford, CA, USA\*\*USA  
JOURNAL: Blood 98 (11 Part 1): p466a November 16, 2001 2001  
MEDIUM: print  
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

2/3/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

12672336 BIOSIS NO.: 199598140169  
Agonistic and antagonistic properties of CD40 mAb G28-5 are dependent on binding valency  
AUTHOR: Ledbetter Jeffrey A (Reprint); Grosmaire Laura S; Hollenbaugh Diane ; Aruffo Alejandro; Nadler Steven G  
AUTHOR ADDRESS: Bristol-Myers Squibb, Pharm. Res. Inst., 3005 First Ave., Seattle, WA 98121, USA\*\*USA  
JOURNAL: Circulatory Shock 44 (2): p67-72 1994 1994  
ISSN: 0092-6213  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

2/3/7 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081529562 EMBASE No: 2006593143  
Cancer: Novel therapeutic strategies that exploit the TNF-related

apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway

Cretney E.; Takeda K.; Smyth M.J.

Cancer Immunology Program, Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Vic. 3002, Australia

AUTHOR EMAIL: mark.smyth@petermac.org

CORRESP. AUTHOR/AFFIL: Smyth M.J.: Cancer Immunology Program, Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Vic. 3002, Australia

CORRESP. AUTHOR EMAIL: mark.smyth@petermac.org

International Journal of Biochemistry and Cell Biology ( Int. J. Biochem. Cell Biol. ) (United Kingdom) January 15, 2007, 39/2 (280-286)

CODEN: IJBBF ISSN: 1357-2725

PUBLISHER ITEM IDENTIFIER: S1357272506002792

DOI: 10.1016/j.biocel.2006.10.005

DOCUMENT TYPE: Journal; Short Survey RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 44

2/3/8 (Item 2 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0077090181 EMBASE No: 1997383451

Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5

Ledbetter J.A.; Francisco J.A.; Siegall C.B.; Gilliland L.K.; Hollenbaugh D.; Aruffo A.; Siadak A.W.; Mischel-Petty N.; Grosmaire L.S.; Gordon M.L.; Brown T.J.; Moran-Davis P.; Mittler R.S.; Kiener P.A.; Nadler S.G.

Bristol-Myers Squibb P., 3005 First Avenue, Seattle, WA 98121, United States

CORRESP. AUTHOR/AFFIL: Nadler S.G.: BMS Pharmaceut. Research Institute, 3005 First Avenue, Seattle, WA 98121, United States

Critical Reviews in Immunology ( CRIT. REV. IMMUNOL. ) (United States)

December 1, 1997, 17/5-6 (427-435)

CODEN: CCRID ISSN: 1040-8401

DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 26

2/3/9 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

143241996 CA: 143(14)241996f PATENT

Methods using a toll-like receptor-2 (TLR2) agonist for treating immunopathological disorders

INVENTOR(AUTHOR): Raz, Eyal; Redecke, Vanessa Doreen; Horner, Anthony A.

LOCATION: USA

ASSIGNEE: The Regents of the University of California

PATENT: PCT International ; WO 200579419 A2 DATE: 20050901

APPLICATION: WO 2005US4895 (20050216) \*US 2004PV545353 (20040217)

PAGES: 50 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;

LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;  
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;  
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ  
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;  
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU;  
MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG  
? t s2/7/1-8

2/7/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18839939 BIOSIS NO.: 200600185334

Humanized anti CD-40 antibody SGN-40 effectively induces cytotoxicity  
against chronic lymphocytic leukemia (CLL) cells through antibody  
mediated cytotoxicity and demonstrates modest biologic evidence of CD40  
activation

AUTHOR: Gowda Aruna C (Reprint); Zhao Xiaobin B; Cheney Carolyn; Mehter  
Najma; Lozanski Gerard; Lin Thomas S; Guster Sara; Drachman J G;  
Muthusamy Natarajan; Byrd John C

AUTHOR ADDRESS: Ohio State Univ, Columbus, OH 43210 USA\*\*USA

JOURNAL: Blood 106 (11, Part 1): p832A NOV 16 2005 2005

CONFERENCE/MEETING: 47th Annual Meeting of the  
American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005;  
20051210

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: The CD40 antigen is involved in cell survival and differentiation  
of B-cells and is uniformly expressed on chronic lymphocytic leukemia  
(CLL) cells. The CD40/CD40L interaction stimulates B-cells, dendritic  
cells and monocytes to proliferate, differentiate, up regulate  
co-stimulatory molecules and increase antigen presentation. While  
activation of CD40 can protect CLL cells against early  
fludarabine-induced apoptosis, these cells become sensitive to delayed  
death by extrinsic pathway apoptosis. (Blood, 105: 3193-8, 2005). SGN-40  
is a humanized anti-CD40 antibody entering clinical trials and has been  
reported to have weak agonistic properties following CD40  
ligation. To pursue rational clinical development of SGN-40, we studied  
the effects of this antibody in fresh, non-cryopreserved primary CLL  
cells. These studies included classic antibody mediated killing  
mechanisms and evidence of both CLL cell activation and protection  
against early fludarabine-mediated apoptosis. CLL cells treated with  
SGN-40 (10 mcg/ml) for 2 hours (hrs) in the presence of human serum  
promoted no complement mediated cytotoxicity (CDC) in 8 pts tested. Direct  
SGN-40 induced apoptosis of human CLL cells with or without anti-Fc IgG  
cross-linking at 24, 48 and 72 hrs was not increased over that observed  
with the isotype control antibody trastuzumab in 8 pis studied. In  
contrast, SGN-40 induced antibody dependent cellular cytotoxicity (ADCC)  
against CLL cells an average of 12% (+/- 11.39 SD, range 2-32%) killing  
at 4 firs (effector to target cell ratio 25: 1) in 6 pts tested. The  
SGN-40 induced ADCC against CLL cells were similar to that observed with  
alemtuzumab (average 19%, SD 6.9, range 10-30%) or \*\*\*rituximab\*\*\*  
(average 18%, SD 12.48, range 8-42.5%). SGN-40 also mediated death in  
Raji and 697 lymphoblastic lymphoma cell lines via ADCC. Similar to  
reports by others with CD40 ligand, SGN-40 mediated activation was noted  
with modest up-regulation of CD80 and HLA-DR at 48hrs. When administered

prior to fludarabine, SGN-40 also protected against death in 5 consecutive samples, although this was less than observed with CD40 ligand transfected HeLa cells, consistent with incomplete CD40 activation. Concurrent administration of SGN-40 and fludarabine did not protect from drug-mediated apoptosis. In conclusion, these findings suggest that SGN-40 has dual property of mediating cytotoxic effect by ADCC and partial CD40 activation. Development of SGN-40 as a therapeutic agent in CLL is justified and future studies by our group are focusing on enhancing SGN-40 mediated ADCC against CLL cells and potentially designing combination studies with SGN-40 to exploit this agent's ability to engage the CD40/CD40L network.

2/7/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18618720 BIOSIS NO.: 200510313220  
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40  
AUTHOR: Law Che-Leung (Reprint); Gordon Kristine A; Collier John; Klussman Kerry; McEarchern Julie A; Cervený Charles G; Mixan Bruce J; Lee Wyne P; Lin Zhonghau; Valdez Patricia; Wahl Alan F; Grewal Iqbal S  
AUTHOR ADDRESS: Seattle Genet Inc, 21823 30th Dr SE, Bothell, WA 98021 USA  
\*\*USA  
AUTHOR E-MAIL ADDRESS: claw@seagen.com  
JOURNAL: Cancer Research 65 (18): p8331-8338 SEP 15 2005 2005  
ISSN: 0008-5472  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: SGN-40 is a humanized IgG1 antihuman CD40 that is currently in a phase I clinical trial for the treatment of multiple myeloma. As surface CD40 expression on B-lineage cells is maintained from pro-B cells to plasma cells, SGN-40 may be applicable to treatment of other B-cell neoplasias, including non-Hodgkin's lymphoma. In this study, we examined potential in vitro and in vivo anti-B-lineage lymphoma activity of SGN-40. Recombinant SGN-40 was expressed and purified from Chinese hamster ovary cells and characterized based on binding affinity, specificity, and normal B-cell stimulation. The ability of SGN-40 to target neoplastic B cells was examined in vitro by proliferation inhibition, cytotoxicity, and antibody-dependent cell cytotoxicity assays and in vivo by human lymphoma xenograft models. Recombinant SGN-40 showed high affinity, K<sub>d</sub> of similar to 1 nmol/L, and specific binding to \*\*\*CD40\*\*\*. Whereas SGN-40 was a weak \*\*\*agonist\*\*\* in stimulating normal B-cell proliferation in the absence of IL-4 and CD40L, it delivered potent proliferation inhibitory and apoptotic signals to, and mediated antibody-dependent cytotoxicity against, a panel of high-grade B-lymphoma lines. These in vitro antilymphoma effects were extended to disseminated and s.c. xenograft CD40 tumor models. In these xenograft models, the antitumor activity of SGN-40 was comparable with that of \*\*\*rituximab\*\*\*. The preclinical in vitro and in vivo antilymphoma activity of SGN40 observed in this study provides a rationale for the clinical testing of SGN-40 in the treatment of CD40(+) B-lineage lymphomas.

2/7/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18576751 BIOSIS NO.: 200510271251

A fully human anti-CD40 antagonistic antibody, CHIR-12.12, inhibit the proliferation of human B cell non-Hodgkin's lymphoma

AUTHOR: Weng Wen-Kai (Reprint); Tong Xia; Luqman Mohammad; Levy Ronald

AUTHOR ADDRESS: Stanford Univ, Sch Med, Stanford, CA 94305 USA\*\*USA

JOURNAL: Blood 104 (11, Part 1): p896A NOV 16 2004 2004

CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004; 20041204

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

**ABSTRACT:** Immunotherapy using anti-tumor antibodies has become a feasible alternative for treating patients with lymphoma. These anti-tumor antibodies may target a specific receptor to disrupt proliferative signaling or mediate their anti-tumoreffect by antibody-dependent cellular cytotoxicity (ADCC) or complement-mediated killing. The CD40 antigen is a good target for such anti-tumor antibodies for several reasons: CD40 is expressed on the vast majority of the non-Hodgkin's B cell lymphomas and it has been proposed that the CD40/CD40L interaction provides a critical survival or proliferative signal for B cell lymphoma, especially the low-grade follicular lymphoma. In addition, B lymphoma cell lines become less sensitive to chemotherapy-induced apoptosis after CD40 cross-linkingin an in vitro study. Therefore, an anti-CD40 antagonist that disrupts the CD40/CD40L interaction and mediates effector mechanism could have a therapeutic advantage. In this report, we describe a fully human anti-CD40 antagonistic IgG1 monoclonal antibody, CHIR-12.12 that was generated from mice with a human immunoglobulin gene loci (XenoMouse (R) mice, Abgenix Inc.). We first compared the antigen expression level of CD40 to the level of CD20, the target for \*\*\*rituximab\*\*\*, on primary lymphoma cells. While the expression level of CD40 was similar between different samples of primary follicular lymphoma cells, it was 10 fold less than the level of \*\*\*CD20\*\*\*. The expression of CD40 and CD20 on chronic lymphocytic leukemia/small lymphocytic lymphoma cells (CLL/SLL) was more variable. However, the level of CD20 was still significantly higher than the level of CD40 in all samples tested (2.4 to 13 fold). While CHIR-12.12 binds to primary lymphoma cells similarly to several other anti-CD40 antibodies, CHIR-12.12 did not induce proliferation of these primary tumore cells. By contrast, an agonist anti-CD40 antibody induced proliferation of these lymphoma cells up to 6-fold over baseline. To study the ability of CHIR-12.12 to interrupt the CD40-CD40L interaction, we cultured lymphoma cells with CD40L-transfected feeder cells in the presence of control IgG1, CHIR-12.12 or \*\*\*rituximab\*\*\*. In this system, the lymphoma cells proliferate in response to CD40-CD40L interaction. The addition of \*\*\*rituximab\*\*\* did not influence the proliferation. However, CHIR-12.12 inhibited the proliferation of follicular lymphoma and of CLL/SLL cells in a dose-dependent manner. The inhibition was observed with antibody concentration at 1mu g/ml and reached maximum of 90% inhibition at 10 mu g/ml. We then evaluated the ability of CHIR-12.12 to elicit complement-mediated killing or ADCC. In vitro, \*\*\*rituximab\*\*\* induced complement-mediated cytotoxicity, while CHIR-12.12 did not. However, both CHIR-12.12 and \*\*\*rituximab\*\*\* induced effective ADCC of primary follicular lymphoma cells using purified NK cells from a healthy donor. Eventhough the level of CD40 is 10-fold less than the level of CD20 on the cell surface of these tumor cells, CHIR-12.12 induced the same degree of ADCC killing as did \*\*\*rituximab\*\*\*. Thus, this novel antagonist CHIR-12.12 antibody both blocks tumor-stimulatory CD40/CD40L

interaction and mediates ADCC in the presence of a low number of target antigen. Our results support further development of this antibody to treat patients with B cell lymphoma.

2/7/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18234887 BIOSIS NO.: 200500141952  
Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival  
AUTHOR: Adams Andrew B; Shirasugi Nozomu; Jones Thomas R; Durham Megan M; Strobert Elizabeth A; Cowan Shannon; Rees Phyllis; Hendrix Rose; Price Karen; Kenyon Norma S; Hagerty David; Townsend Robert; Hollenbaugh Dianne; Pearson Thomas C (Reprint); Larsen Christian P  
AUTHOR ADDRESS: Dept Surg, Emory Transplant Ctr, Suite 5105, Woodruff Mem Res Bldg, 101 Woodruff Cir, Atlanta, GA, 30332, USA\*\*USA  
AUTHOR E-MAIL ADDRESS: tpearson@emoryhealthcare.org;  
clarsen@emoryhealthcare.org  
JOURNAL: Journal of Immunology 174 (1): p542-550 January 1, 2005 2005  
MEDIUM: print  
ISSN: 0022-1767 \_(ISSN print)  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: In recent years, reagents have been developed that specifically target signals critical for effective T cell activation and function. Manipulation of the CD28/CD80/86 and CD40/CD154 pathways has exhibited extraordinary efficacy, particularly when the pathways are blocked simultaneously. Despite the reported efficacy of anti-CD154 in rodents and higher models, its future clinical use is uncertain due to reported thromboembolic events in clinical trials. To circumvent this potential complication, we developed and evaluated a chimeric Ab targeting CD40 (Chi220, BMS-224819) as an alternative to CD154. Although Chi220 blocks CD154 binding, it also possesses partial agonist properties and weak stimulatory potential. The anti- \*\*\*CD40\*\*\* was tested alone. and in combination with a rationally designed, high affinity variant of CTLA4-1g, LEA29Y (belatacept), in a nonhuman primate model of islet transplantation. Although either agent alone only modestly prolonged islet survival (Chi220 alone: 14, 16, and. 84 days; LEA29Y alone: 58 and 60 days), their combination (LEA29Y and Chi220) dramatically facilitated long term survival (237, 237, 220, >185, and 172 days). We found that the effects of Chi220 treatment were not mediated solely through deletion of CD20-bearing cells and that the combined therapy did not significantly impair established antiviral immunity.

2/7/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

16647704 BIOSIS NO.: 200200241215  
Human anti-CD40 antagonistic antibodies inhibit the proliferation of human B cell non-Hodgkin's lymphoma  
AUTHOR: Wong Wen-Kai (Reprint); Wang Changyu; Chu Keting; Levy Ronald (Reprint)  
AUTHOR ADDRESS: Medicine/Oncology, Stanford University, Stanford, CA, USA\*\*USA  
JOURNAL: Blood 98 (11 Part 1): p466a November 16, 2001 2001



MEDIUM: print

CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: CD40 is expressed on the vast majority of the non-Hodgkin's B cell lymphomas. It has been proposed that the CD40/CD40L interaction provides a critical survival or proliferative signal for B cell lymphoma, especially the low-grade follicular lymphoma. In addition, B lymphoma cell lines become less sensitive to chemotherapy-induced apoptosis after CD40 cross-linking in an in vitro study (Walker et al. Cancer Res. 1997, 57:1939), probably via the up-regulation of a death-suppressor protein, BCL-xL. Therefore, a potential therapeutic strategy would be to develop an anti-CD40 blocking antibody (antagonist) that could disrupt the CD40/CD40L interaction. Such a reagent could be used alone or in combination with other therapeutic modalities, eg. chemotherapy. In this report, we describe four human anti-CD40 antibodies, 2F5 (IgG) and 15B8 (IgG2) (antagonists); 12C3.2 (IgG1) and MS81 (IgG2) (agonists), that were generated from transgenic mice whose immunoglobulin gene locus were replaced with human IgG immunoglobulin gene locus. All four antibodies stain tumor cells from patients with follicular lymphoma to a similar degree. However, while the anti-CD40 agonistic antibodies up-regulated the cell surface Fas, B7-1, B7-2 and VCAM-1 on follicular lymphoma cells, neither of the two anti-CD40 antagonistic antibodies has any effect on the expression of these molecules. Follicular lymphoma cells isolated from biopsy samples showed minimal proliferative activity when cultured with medium alone. The anti-CD40 agonistic antibodies induced proliferation of these follicular lymphoma cells up to 10 fold over baseline. In contrast, the antagonistic antibodies 2F5 and 15B8 showed no such effect. In one case, 2F5 inhibited the baseline proliferation of the tumor cells by 70%. We then tested the ability of these two anti-CD40 antagonistic antibodies to interrupt the CD40-CD40L interaction. To study this, we cultured follicular lymphoma cells With CD40L-transfected feeder cells in the presence of different antibodies. In this system, the follicular lymphoma cells proliferate in response to CD40-CD40L interaction. The addition of control Ig or anti-CD40 agonistic antibodies did not influence the proliferation. However, both 2F5 and 15B8 inhibited the proliferation of lymphoma cells in this system in a dose-dependent manner. The inhibition was more pronounced with 2F5 (maximum 95% inhibition) than with 15B8 (maximum 65% inhibition). This inhibition of CD40L-driven proliferation of tumor cells was observed in all of 6 follicular lymphoma patient samples tested, including 4 samples from patients who were refractory to previous Rituximab therapy. Inhibition was also observed in one mantle cell lymphoma sample. Additional studies are in progress to evaluate the ability of these two anti-CD40 antagonistic antibodies to elicit complement-mediated and antibody-dependent cellular cytotoxicities, and their potential to use in treating patients with B cell non-Hodgkin's lymphoma.

2/7/6 (Item 6 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

12672336 BIOSIS NO.: 199598140169

Agonistic and antagonistic properties of CD40 mAb G28-5 are

dependent on binding valency  
AUTHOR: Ledbetter Jeffrey A (Reprint); Grosmaire Laura S; Hollenbaugh Diane  
; Aruffo Alejandro; Nadler Steven G  
AUTHOR ADDRESS: Bristol-Myers Squibb, Pharm. Res. Inst., 3005 First Ave.,  
Seattle, WA 98121, USA\*\*USA  
JOURNAL: Circulatory Shock 44 (2): p67-72 1994 1994  
ISSN: 0092-6213  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: CD40 functional responses can be triggered by binding of mAb G28-5. Here we show that G28-5 induces partial CD40 responses and functions as a partial antagonist of natural CD40 ligand, gp39, by preventing gp39 binding. Fab fragments of G28-5 retain inhibitory activity but lose crosslinking-dependent stimulatory activity. The synergistic interaction of CD40 signals with PMA or CD20 show differential requirements for CD40 crosslinking and different sensitivity to cyclosporine A, suggesting that CD40 receptor may use different effector mechanisms for synergy with calcium-dependent CD20 signals or with calcium-independent signals from PMA. Activation of NF-kappa-B occurred in RAJI cells by G28-5 or by gp39 treatment, and was CD40 crosslinking-dependent. These results suggest that activation of NF-kappa-B is involved in some CD40 receptor signals and may be related to CD40 effects on stimulation or inhibition of apoptosis.

2/7/7 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081529562 EMBASE No: 2006593143  
Cancer: Novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway  
Cretney E.; Takeda K.; Smyth M.J.  
Cancer Immunology Program, Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Vic. 3002, Australia  
AUTHOR EMAIL: mark.smyth@petermac.org  
CORRESP. AUTHOR/AFFIL: Smyth M.J.: Cancer Immunology Program, Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Vic. 3002, Australia  
CORRESP. AUTHOR EMAIL: mark.smyth@petermac.org

International Journal of Biochemistry and Cell Biology ( Int. J. Biochem. Cell Biol. ) (United Kingdom) January 15, 2007, 39/2 (280-286)  
CODEN: IJBBF ISSN: 1357-2725  
PUBLISHER ITEM IDENTIFIER: S1357272506002792  
DOI: 10.1016/j.biocel.2006.10.005  
DOCUMENT TYPE: Journal; Short Survey RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 44  
Cancer is a widespread disease, with half of all men and one-third of all women in the United States developing cancer during their lifetime. The efficacy of many cancer treatments including radiotherapy, chemotherapy and immunotherapy is due to their ability to induce tumor cell apoptosis. Recombinant tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is currently being developed as a cancer therapeutic since it selectively induces apoptosis in a variety of transformed cells, but not in most normal cells. Agonistic monoclonal antibodies (mAbs) specific for human death-inducing TRAIL receptors (DR4 or DR5) are also being actively pursued. Importantly, in experimental mice, synergistic anti-tumor effects

have been observed with a combination treatment of agonistic mAb against DR5 together with either IL-21 or agonistic mAbs against CD40 and CD137. Together, these findings suggest that antibody-based therapies that cause tumor cell apoptosis and promote T cell memory or function may be effective in fighting cancer. Crown Copyright (c) 2006.

2/7/8 (Item 2 from file: 73)  
 DIALOG(R)File 73:EMBASE  
 (c) 2008 Elsevier B.V. All rts. reserv.

0077090181 EMBASE No: 1997383451

Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5

Ledbetter J.A.; Francisco J.A.; Siegall C.B.; Gilliland L.K.; Hollenbaugh D.; Aruffo A.; Siadak A.W.; Mischel-Petty N.; Grosmaire L.S.; Gordon M.L.; Brown T.J.; Moran-Davis P.; Mittler R.S.; Kiener P.A.; Nadler S.G.  
 Bristol-Myers Squibb P., 3005 First Avenue, Seattle, WA 98121, United States

CORRESP. AUTHOR/AFFIL: Nadler S.G.: BMS Pharmaceut. Research Institute, 3005 First Avenue, Seattle, WA 98121, United States

Critical Reviews in Immunology ( CRIT. REV. IMMUNOL. ) (United States)  
 December 1, 1997, 17/5-6 (427-435)  
 CODEN: CCRID ISSN: 1040-8401  
 DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Abstract  
 LANGUAGE: English SUMMARY LANGUAGE: English  
 NUMBER OF REFERENCES: 26

A single-chain Fv (sFv) was expressed from the variable regions of the CD40-specific mAb (328-5. The molecule bound CD40 with a high affinity (2.2 nM) and was a monomer in solution. Surprisingly, G28-5 sFv was a potent CD40 agonist that rapidly crosslinked CD40 on the cell surface but did not crosslink CD4-Ig in solution. G28-5 sFv was a more potent agonist than G28-5 IgG and was able to stimulate CD40 responses by B cells and monocytes. G28-5 IgG partially blocked, whereas G28-5 sFv augmented CD40 responses during stimulation with natural ligand (gp39-CD8 fusion protein). These results indicate that the functional activity of ligands built from the binding site of G28-5 is highly dependent upon the size and physical properties of the molecule both in solution and on the cell surface.

? s (cd40)(10n)(antibod? or immunoglobulin?) and (cd20 or rituxan or rituximab)

34908 CD40  
 2338190 ANTIBOD?  
 884163 IMMUNOGLOBULIN?  
 7673 CD40(10N)(ANTIBOD? OR IMMUNOGLOBULIN?)  
 21687 CD20  
 1876 RITUXAN  
 20705 RITUXIMAB

S3 434 (CD40)(10N)(ANTIBOD? OR IMMUNOGLOBULIN?) AND (CD20 OR RITUXAN OR RITUXIMAB)

? s s3 and (cancer? or tumor? or neoplas? or tumour? or leukemia? or lymphoma?)  
 Processing

434 S3  
 3028776 CANCER?  
 3189463 TUMOR?  
 3114698 NEOPLAS?  
 379571 TUMOUR?  
 701810 LEUKEMI?  
 400997 LYMPHOMA?  
 S4 280 S3 AND (CANCER? OR TUMOR? OR NEOPLAS? OR TUMOUR? OR

```

LEUKEMI? OR LYMPHOMA?)
? rd s4
  S5      241  RD S4  (unique items)
? s s5 and (cd40)20n)(agonist? or stimulat? or increas?)
>>>Unmatched parentheses
? s s5 and (cd40)(20n)(agonist? or stimulat? or increas?)
Processing
      241  S5
      34908  CD40
      589238  AGONIST?
      2742672  STIMULAT?
      7853004  INCREAS?
      9496  CD40(20N)((AGONIST? OR STIMULAT?) OR INCREAS?)
  S6      24  S5 AND (CD40)(20N)(AGONIST? OR STIMULAT? OR INCREAS?)
? rd s6
  S7      24  RD S6  (unique items)
? t s7/3/all

```

```

7/3/1      (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

```

```

0020168862  BIOSIS NO.: 200800215801
hCD122, an antagonist human Anti-CD40 monoclonal antibody,
enhances efficacy of CHOP in tumor xenograft model of human diffuse
large B-Cell ***lymphoma*** .
AUTHOR: Luqman Mohammad (Reprint); Hsu Ssucheng J; Ericson Matthew;
Klabunde Sha; Kantak Seema
AUTHOR ADDRESS: Inst Biomed Res, Emeryville, CA USA**USA
JOURNAL: Blood 110 (11, Part 1): p162A NOV 16 2007 2007
CONFERENCE/MEETING: 49th Annual Meeting of the
American-Society-of-Hematology Atlanta, GA, USA December 08 -11, 2007;
20071208
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

```

```

7/3/2      (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

```

```

0019597945  BIOSIS NO.: 200700257686
Delayed redistribution of CD27, CD40 and CD80 positive B cells and
the impaired in vitro immunoglobulin G production in patients with
non-hodgkin ***lymphoma*** treated with ***rituximab*** .
AUTHOR: Nishio Mitsufumi (Reprint); Fujimoto Katsuya; Yamamoto Satoshi;
Sakai Toshiya; Kumano Kohki; Obara Masato; Koizumi Kazuki; Mukai Masaya;
Sato Norihiro; Koike Takao
AUTHOR ADDRESS: Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan**
Japan
JOURNAL: Blood 108 (11, Part 1): p280A NOV 16 2006 2006
CONFERENCE/MEETING: 48th Annual Meeting of the
American-Society-of-Hematology Orlando, FL, USA December 09 -12, 2006;
20061209
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Abstract

```

LANGUAGE: English

7/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18839939 BIOSIS NO.: 200600185334  
Humanized anti CD-40 antibody SGN-40 effectively induces cytotoxicity  
against chronic lymphocytic leukemia (CLL) cells through  
antibody mediated cytotoxicity and demonstrates modest biologic  
evidence of CD40 activation  
AUTHOR: Gowda Aruna C (Reprint); Zhao Xiaobin B; Cheney Carolyn; Mehter  
Najma; Lozanski Gerard; Lin Thomas S; Guster Sara; Drachman J G;  
Muthusamy Natarajan; Byrd John C  
AUTHOR ADDRESS: Ohio State Univ, Columbus, OH 43210 USA\*\*USA  
JOURNAL: Blood 106 (11, Part 1): p832A NOV 16 2005 2005  
CONFERENCE/MEETING: 47th Annual Meeting of the  
American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005;  
20051210  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster  
RECORD TYPE: Abstract  
LANGUAGE: English

7/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18618720 BIOSIS NO.: 200510313220  
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal  
antibody, SGN-40  
AUTHOR: Law Che-Leung (Reprint); Gordon Kristine A; Collier John; Klussman  
Kerry; McEarchern Julie A; Cervený Charles G; Mixan Bruce J; Lee Wyne P;  
Lin Zhonghau; Valdez Patricia; Wahl Alan F; Grewal Iqbal S  
AUTHOR ADDRESS: Seattle Genet Inc, 21823 30th Dr SE, Bothell, WA 98021 USA  
\*\*USA  
AUTHOR E-MAIL ADDRESS: claw@seagen.com  
JOURNAL: Cancer Research 65 (18): p8331-8338 SEP 15 2005 2005  
ISSN: 0008-5472  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

7/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18576751 BIOSIS NO.: 200510271251  
A fully human anti- \*\*\*CD40\*\*\* antagonistic \*\*\*antibody\*\*\* , CHIR-12.12,  
inhibit the proliferation of human B cell non-Hodgkin's lymphoma  
AUTHOR: Weng Wen-Kai (Reprint); Tong Xia; Luqman Mohammad; Levy Ronald  
AUTHOR ADDRESS: Stanford Univ, Sch Med, Stanford, CA 94305 USA\*\*USA  
JOURNAL: Blood 104 (11, Part 1): p896A NOV 16 2004 2004  
CONFERENCE/MEETING: 46th Annual Meeting of the  
American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004;  
20041204  
SPONSOR: Amer Soc Hematol

ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster  
RECORD TYPE: Abstract  
LANGUAGE: English

7/3/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18575974 BIOSIS NO.: 200510270474  
In vitro activity of a novel fully human anti-CD40 antibody  
CHIR-12.12 in chronic lymphocytic \*\*\*leukemia\*\*\* : Blockade of \*\*\*CD40\*\*\*  
activation and induction of ADCC.  
AUTHOR: Tong Xia (Reprint); Georgakis Georgios V; Li Long; Susan O'Brien;  
Anas Younes; Mohammad Luqman  
AUTHOR ADDRESS: Chiron Corp, Res and Dev, Emeryville, CA 94608 USA\*\*USA  
JOURNAL: Blood 104 (11, Part 1): p686A NOV 16 2004 2004  
CONFERENCE/MEETING: 46th Annual Meeting of the  
American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004;  
20041204  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster  
RECORD TYPE: Abstract  
LANGUAGE: English

7/3/7 (Item 7 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18575884 BIOSIS NO.: 200510270384  
A fully human antagonist anti-CD40 antibody triggers  
significant antitumor activity against human multiple myeloma  
AUTHOR: Tai Yu-Tzu (Reprint); Li Xian-Feng; Tong Xia; Catley Laurence;  
Santos Daniel; Tournilhac Olivier; Schlossman Robert; Richardson Paul;  
Munshi Nikhil C; Luqman Mohammad; Anderson Kenneth C  
AUTHOR ADDRESS: Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper  
Multiple Myeloma Ctr, Boston, MA 02115 USA\*\*USA  
JOURNAL: Blood 104 (11, Part 1): p663A-664A NOV 16 2004 2004  
CONFERENCE/MEETING: 46th Annual Meeting of the  
American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004;  
20041204  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster  
RECORD TYPE: Abstract  
LANGUAGE: English

7/3/8 (Item 8 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18572914 BIOSIS NO.: 200510267414  
Regulation of Berg-36 gene expression by survival and apoptotic stimuli in  
B-chronic lymphocytic leukaemia cells.  
AUTHOR: Jewell Andrew P (Reprint); Baou Maria; Yong Kwee L; Carr Robert;  
Murphy John  
AUTHOR ADDRESS: Kingston Univ, Kingston upon Thames KT1 2EE, Surrey, UK\*\*UK

JOURNAL: Blood 104 (11, Part 2): p275B NOV 16 2004 2004  
CONFERENCE/MEETING: 46th Annual Meeting of the  
American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004;  
20041204  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

7/3/9 (Item 9 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

17781046 BIOSIS NO.: 200400147707  
Comparative efficacy of Rituximab and a fully human anti-CD40  
antagonist antibody in in vitro and in xenograft lymphoma  
models.  
AUTHOR: Long Li (Reprint); Tong Xia (Reprint); Patawaran Montesa (Reprint);  
Luqman Mohammad (Reprint)  
AUTHOR ADDRESS: Research, Chiron Corporation, Emeryville, CA, USA\*\*USA  
JOURNAL: Blood 102 (11): p646a November 16, 2003 2003  
MEDIUM: print  
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of  
Hematology San Diego, CA, USA December 06-09, 2003; 20031206  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

7/3/10 (Item 10 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

16647704 BIOSIS NO.: 200200241215  
Human anti-CD40 antagonistic antibodies inhibit the  
proliferation of human B cell non-Hodgkin's lymphoma  
AUTHOR: Weng Wen-Kai (Reprint); Wang Changyu; Chu Keting; Levy Ronald  
(Reprint)  
AUTHOR ADDRESS: Medicine/Oncology, Stanford University, Stanford, CA, USA\*\*  
USA  
JOURNAL: Blood 98 (11 Part 1): p466a November 16, 2001 2001  
MEDIUM: print  
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of  
Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

7/3/11 (Item 11 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

13701505 BIOSIS NO.: 199799335565  
Increased inhibition of proliferation of human B cell lymphomas

following ligation of CD40, and either CD19, CD20, CD95 or  
surface immunoglobulin  
AUTHOR: Benoit Nicole E; Wade William F (Reprint)  
AUTHOR ADDRESS: Dep. Microbiol., Dartmouth Med. Sch., Lebanon, NH 03756,  
USA\*\*USA  
JOURNAL: Immunopharmacology 35 (2): p129-139 1996 1996  
ISSN: 0162-3109  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

7/3/12 (Item 12 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

13000597 BIOSIS NO.: 199598468430  
Antibodies to CD40 prevent Epstein-Barr virus-mediated human  
B-cell lymphomagenesis in severe combined immune deficient mice  
given human peripheral blood lymphocytes  
AUTHOR: Murphy William J (Reprint); Funakoshi Satoshi; Beckwith Margaret;  
Rushing Susan E; Conley Denise K; Armitage Richard J; Fanslow William C;  
Rager Helen C; Taub Dennis D; Ruscetti Francis W; Longo Dan L  
AUTHOR ADDRESS: Biol. Carcinogenesis and Dev. Program, Program Resources  
Inc./DynCorp, NCI-FCRDC, Build. 567, Room 141, Frederick, MD 21702-1201,  
USA\*\*USA  
JOURNAL: Blood 86 (5): p1946-1953 1995 1995  
ISSN: 0006-4971  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

7/3/13 (Item 13 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

11307186 BIOSIS NO.: 199294009027  
IL-4 INDUCES CONFORMATIONAL CHANGE OF CD20 ANTIGEN VIA A PROTEIN  
KINASE C-INDEPENDENT PATHWAY ANTAGONISTIC EFFECT OF ANTI-CD40  
MONOCLONAL ANTIBODY  
AUTHOR: DANCESCU M (Reprint); WU C; RUBIO M; DELESPESE G; SARFATI M  
AUTHOR ADDRESS: ALLERGY RES LAB, NOTRE-DAME HOSP RES CENT, 1560 SHERBROOKE  
ST EAST, MONTREAL, QUE H2L 4M1\*\*CANADA  
JOURNAL: Journal of Immunology 148 (8): p2411-2416 1992  
ISSN: 0022-1767  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

7/3/14 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081529562 EMBASE No: 2006593143  
Cancer: Novel therapeutic strategies that exploit the TNF-related  
apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway  
Cretney E.; Takeda K.; Smyth M.J.  
Cancer Immunology Program, Trescowthick Research Laboratories, Peter  
MacCallum Cancer Centre, East Melbourne, Vic. 3002, Australia



AUTHOR EMAIL: mark.smyth@petermac.org  
CORRESP. AUTHOR/AFFIL: Smyth M.J.: Cancer Immunology Program,  
Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East  
Melbourne, Vic. 3002, Australia  
CORRESP. AUTHOR EMAIL: mark.smyth@petermac.org

International Journal of Biochemistry and Cell Biology ( Int. J. Biochem.  
Cell Biol. ) (United Kingdom) January 15, 2007, 39/2 (280-286)  
CODEN: IJBBF ISSN: 1357-2725  
PUBLISHER ITEM IDENTIFIER: S1357272506002792  
DOI: 10.1016/j.biocel.2006.10.005  
DOCUMENT TYPE: Journal; Short Survey RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 44

7/3/15 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080759169 EMBASE No: 2005403690  
New treatments for SLE: Cell-depleting and anti-cytokine therapies  
Anolik J.H.; Aringer M.  
Allergy, Immunology and Rheumatology Unit, Department of Medicine,  
University of Rochester School of Medicine and Dentistry, Rochester, NY  
14642, United States  
AUTHOR EMAIL: jennifer; anolik@urmc.rochester.edu  
CORRESP. AUTHOR/AFFIL: Anolik J.H.: Allergy, Immunology and Rheumatology  
Unit, Department of Medicine, University of Rochester School of Medicine  
and Dentistry, Rochester, NY 14642, United States  
CORRESP. AUTHOR EMAIL: jennifer; anolik@urmc.rochester.edu

Best Practice and Research in Clinical Rheumatology ( Best Pract. Res.  
Clin. Rheumatol. ) (United Kingdom) October 1, 2005, 19/5 SPEC. ISS.  
(859-878)  
CODEN: BPRCC ISSN: 1521-6942  
PUBLISHER ITEM IDENTIFIER: S1521694205000707  
DOI: 10.1016/j.berh.2005.05.006  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 121

7/3/16 (Item 3 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080467107 EMBASE No: 2005111263  
Fc receptor targeting in the treatment of allergy, autoimmune diseases  
and cancer  
Nakamura A.; Akiyama K.; Takai T.  
Tohoku University, Dept. of Experimental Immunology, Inst. of Development  
ageing/Cancer, Seiryō 4-1, Sendai 980-8575, Japan  
AUTHOR EMAIL: aki@idac.tohoku.ac.jp  
CORRESP. AUTHOR/AFFIL: Nakamura A.: Tohoku University, Dept. of  
Experimental Immunology, Inst. of Development ageing/Cancer, Seiryō 4-1,  
Sendai 980-8575, Japan  
CORRESP. AUTHOR EMAIL: aki@idac.tohoku.ac.jp

Expert Opinion on Therapeutic Targets ( Expert Opin. Ther. Targets ) (  
United Kingdom) February 1, 2005, 9/1 (169-190)

CODEN: EOTTA ISSN: 1472-8222  
DOI: 10.1517/14728222.9.1.169  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 189

7/3/17 (Item 4 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0076676499 EMBASE No: 1996352908  
Increased inhibition of proliferation of human B cell  
lymphomas following ligation of CD40, and iehter CD19,  
CD20, CD95 or surface immunoglobulin  
Benoit N.E.; Wade W.F.  
Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756,  
United States  
AUTHOR EMAIL: william.wade@dartmouth.edu  
CORRESP. AUTHOR/AFFIL: Wade W.F.: Department of Microbiology, Dartmouth  
Medical School, Lebanon, NH 03756, United States

Immunopharmacology ( IMMUNOPHARMACOLOGY ) (Netherlands) November 1, 1996  
, 35/2 (129-139)  
CODEN: IMMUD ISSN: 0162-3109  
PUBLISHER ITEM IDENTIFIER: S0162310996001385  
DOI: 10.1016/S0162-3109(96)00138-5  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 33

7/3/18 (Item 5 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0075416581 EMBASE No: 1993196137  
CD40 plays an essential role in the activation of human B cells by murine  
EL4B5 cells  
Kwekkeboom J.; De Boer M.; Tager J.M.; De Groot C.  
Lab. of Cell Biology and Histology, University of Amsterdam, Academic  
Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, Netherlands  
CORRESP. AUTHOR/AFFIL: Kwekkeboom J.: Lab. of Cell Biology and Histology,  
University of Amsterdam, Academic Medical Center, Meibergdreef 15, 1105 AZ  
Amsterdam, Netherlands

Immunology ( IMMUNOLOGY ) (United Kingdom) July 28, 1993, 79/3 (439-444)  
CODEN: IMMUA ISSN: 0019-2805  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English

7/3/19 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2008 Dialog. All rts. reserv.

14671788 PMID: 12072193  
CM1 ligation initiates apoptosis in a caspase 8-dependent manner in Ramos  
cells and in a mitochondria-controlled manner in Raji cells.  
Kim Daejin; Hur Dae Young; Kim Yeong Seok; Lee Kyungmi; Lee Youngseon;  
Cho Daeho; Kang Jae Seung; Kim Young-in; Hahm Eunsil; Yang Yoolhee; Yoon

Suyoung; Kim Seonghan; Lee Won Bok; Park Hae Young; Kim Yoon Berm; Hwang Young-il; Chang Ka Y; Lee Wang Jae

Department of Anatomy, Seoul National University, College of Medicine and Institute of Allergy and Clinical Immunology, Medical Research Center, Seoul National University, Seoul, South Korea.

Human immunology (United States) Jul 2002, 63 (7) p576-87, ISSN 0198-8859--Print Journal Code: 8010936

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

7/3/20 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

13206298 PMID: 10092062

Expression of CD40/CD40 ligand and Bcl-2 family proteins in labial salivary glands of patients with Sjogren's syndrome.

Nakamura H; Kawakami A; Tominaga M; Migita K; Kawabe Y; Nakamura T; Eguchi K

First Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki City, Japan.

Laboratory investigation; a journal of technical methods and pathology (UNITED STATES) Mar 1999, 79 (3) p261-9, ISSN 0023-6837--Print

Journal Code: 0376617

Publishing Model Print

Document type: Journal Article; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

7/3/21 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

147110188 CA: 147(6)110188d PATENT

Use of stimulatory anti-CD40 antibodies in the treatment of diseases associated with aberrant CD40 presentation on cell surfaces

INVENTOR(AUTHOR): Drachman, Jonathan; Law, Che-Leung; Lewis, Tim

LOCATION: USA

ASSIGNEE: Seattle Genetics, Inc.

PATENT: PCT International ; WO 200775326 A2 DATE: 20070705

APPLICATION: WO 2006US47308 (20061211) \*US 2005PV749246 (20051209) \*US 2006PV811353 (20060605) \*US 2006PV811301 (20060605) \*US 2006PV847234 (20060925)

PAGES: 125pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0039/395 A I F B 20060101 H US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;

MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM;  
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

7/3/22 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

144231465 CA: 144(13)231465p PATENT  
Humanized antibodies with Man3GlcNAc2 modification to increase  
FcγRIII receptor binding and ADCC for therapeutic use  
INVENTOR(AUTHOR): Gerngross, Tillman U.; Li, Huijuan; Wildt, Stefan  
LOCATION: USA  
PATENT: U.S. Pat. Appl. Publ. ; US 20060034829 A1 DATE: 20060216  
APPLICATION: US 2005187079 (20050721) \*US 2001PV344169 (20011227) \*WO  
2002US41510 (20021224) \*US 2004PV589913 (20040721) \*US 2004PV589937  
(20040721) \*US 2005500240 (20050323)  
PAGES: 47 pp., Cont.-in-part of U.S. Ser. No. 500,240. CODEN: USXXCO  
LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: 424130100  
IPCR/8 + Level Value Position Status Version Action Source Office:  
C07K-0016/28 A I F B 20060101 20060216 H US  
C07H-0021/04 A I L B 20060101 20060216 H US  
C12P-0021/06 A I L B 20060101 20060216 H US  
A61K-0039/395 A I L B 20060101 20060216 H US  
C12N-0005/06 A I L B 20060101 20060216 H US

7/3/23 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

144005405 CA: 144(1)5405n PATENT  
Antibody glycosylation variants having increased antibody-dependent  
cellular cytotoxicity  
INVENTOR(AUTHOR): Umana, Pablo; Jean-Mairet, Joel; Bailey, James E.  
LOCATION: Switz.  
ASSIGNEE: Glycart Biotechnology AG  
PATENT: U.S. Pat. Appl. Publ. ; US 20050272128 A1 DATE: 20051208  
APPLICATION: US 2005199232 (20050809) \*US 2002211554 (20020805) \*US  
2003633697 (20030805)  
PAGES: 28 pp., Cont.-in-part of U.S. Ser. No. 633,697. CODEN: USXXCO  
LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: 435069100; C07K-016/28A; C07H-021/04B; C12P-021/06B;  
C12N-005/06B

7/3/24 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

141172878 CA: 141(11)172878p PATENT  
Engineering of glycosylation profile of antibody Fc region to increase Fc  
receptor binding affinity and effector function for treating cancer  
INVENTOR(AUTHOR): Umana, Pablo; Bruenker, Peter; Ferrara, Claudia; Suter,  
Tobias  
LOCATION: Switz.  
ASSIGNEE: Glycart Biotechnology Ag  
PATENT: PCT International ; WO 200465540 A2 DATE: 20040805

APPLICATION: WO 2004IB844 (20040122) \*US PV441307 (20030122) \*US PV491254 (20030731) \*US PV495142 (20030815)

PAGES: 231 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C12N-000/A

DESIGNATED COUNTRIES: AE; AE; AG; AL; AL; AM; AM; AM; AT; AT; AU; AZ; AZ; BA; BB; BG; BG; BR; BR; BW; BY; BY; BZ; BZ; CA; CH; CN; CN; CO; CO; CR; CR; CU; CU; CZ; CZ; DE; DE; DK; DK; DM; DZ; EC; EC; EE; EE; EG; ES; ES; FI; FI; GB; GD; GE; GE; GH; GM; HR; HR; HU; HU; ID; IL; IN; IS; JP; JP; KE; KE; KG; KG; KP; KP; KR; KR; KZ; KZ; KZ; LC; LK; LR; LS; LS; LT; LU; LV; MA; MD; MD; MG; MK; MN; MW; MX; MX; MZ; MZ; NA; NI  
? t s7/7/17

7/7/17 (Item 4 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0076676499 EMBASE No: 1996352908

Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and iehter CD19, CD20, CD95 or surface immunoglobulin

Benoit N.E.; Wade W.F.

Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756, United States

AUTHOR EMAIL: william.wade@dartmouth.edu

CORRESP. AUTHOR/AFFIL: Wade W.F.: Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756, United States

Immunopharmacology ( IMMUNOPHARMACOLOGY ) (Netherlands) November 1, 1996 , 35/2 (129-139)

CODEN: IMMUD ISSN: 0162-3109

PUBLISHER ITEM IDENTIFIER: S0162310996001385

DOI: 10.1016/S0162-3109(96)00138-5

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 33

Non-Hodgkin's (NHL) B cell lymphomas are growth-inhibited by ligation of their CD40 molecules. This inhibition is not absolute in that ~50% of the cells are not inhibited. We conducted studies to see if other signals that have been reported to inhibit B cell lymphoma growth could be used in combination with anti-CD40 signaling to completely inhibit growth. Ligation of surface \*\*\*immunoglobulin\*\*\* (Ig), CD19, CD20, CD37 or CD95 with soluble antibody did not affect growth of the panel of NHL cells examined. Ligation of \*\*\*CD20\*\*\*, CD19 or CD95 was inhibitory for some NHL cell lines if the primary antibody was crosslinked with a secondary \*\*\*antibody\*\*\*. Combining anti- \*\*\*CD40\*\*\* with anti-CD19, anti-CD20, or anti-Ig resulted in increased inhibition past that produced by anti- \*\*\*CD40\*\*\* alone. The additive effect of anti-CD40 and other antibodies to selected surface markers was not observed in all NHL cell lines. Crosslinking of CD95 was also growth inhibitory for the majority of the NHL, and when combined with anti-CD40 under conditions that afforded crosslinking of the two receptors, increased inhibition was seen in three of the NHL cell lines. We found that cAMP or sodium butyrate (NaB) were also effective at inhibiting growth of the NHL cells; this was a profound inhibition (approaching 100%) compared to the 50% inhibition seen with anti-CD40 treatment. The potential for anti-CD40 and either cAMP or NaB to be additive was tested and not found to be the case. The ability to inhibit proliferation of the NHL was very dynamic with some antibody combinations being either inhibitory for multiple cells, not having an effect at all, or

in some cases being stimulatory. This suggests that the NHL may represent unique stages of B cells that might serve as a model system which could be developed to precisely categorize patient NHL.

? ds

Set	Items	Description
S1	15	(CD40)(10N)(AGONIST?) AND (CD20 OR RITUXAN OR RITUXIMAB)
S2	9	RD S1 (unique items)
S3	434	(CD40)(10N)(ANTIBOD? OR IMMUNOGLOBULIN?) AND (CD20 OR RITUXAN OR RITUXIMAB)
S4	280	S3 AND (CANCER? OR TUMOR? OR NEOPLAS? OR TUMOUR? OR LEUKEM- I? OR LYMPHOMA?)
S5	241	RD S4 (unique items)
S6	24	S5 AND (CD40)(20N)(AGONIST? OR STIMULAT? OR INCREAS?)
S7	24	RD S6 (unique items)

? s s (cd40?)(20n)(agonist? or stimulat? or increas?) and (cd20 or rituxan or rituximab)

Processing

	0	S (CD40?)
	589238	AGONIST?
	2742672	STIMULAT?
	7853004	INCREAS?
	0	S (CD40?)(20N)((AGONIST? OR STIMULAT?) OR INCREAS?)
	21687	CD20
	1876	RITUXAN
	20705	RITUXIMAB
S8	0	S (CD40?)(20N)(AGONIST? OR STIMULAT? OR INCREAS?) AND (CD20 OR RITUXAN OR RITUXIMAB)

? s (cd40?)(20n)(agonist? or stimulat? or increas?) and (cd20 or rituxan or rituximab)

	36447	CD40?
	589238	AGONIST?
	2742672	STIMULAT?
	7853004	INCREAS?
	10844	CD40?(20N)((AGONIST? OR STIMULAT?) OR INCREAS?)
	21687	CD20
	1876	RITUXAN
	20705	RITUXIMAB
S9	193	(CD40?)(20N)(AGONIST? OR STIMULAT? OR INCREAS?) AND (CD20 OR RITUXAN OR RITUXIMAB)

? rd s9

S10	105	RD S9 (unique items)
-----	-----	----------------------

? s s10 and(tumor? or tumour? or cancer? or neoplas? or leukemia? or lymphoma?)

Processing

	105	S10
	3189463	TUMOR?
	379571	TUMOUR?
	3028776	CANCER?
	3114698	NEOPLAS?
	701810	LEUKEMI?
	400997	LYMPHOMA?
S11	57	S10 AND(TUMOR? OR TUMOUR? OR CANCER? OR NEOPLAS? OR LEUKEMI? OR LYMPHOMA?)

? rd s11

S12	57	RD S11 (unique items)
-----	----	-----------------------

? t s12/3/all

0020168862 BIOSIS NO.: 200800215801

hCD122, an antagonist human Anti-CD40 monoclonal antibody, enhances efficacy of CHOP in tumor xenograft model of human diffuse large B-Cell \*\*\*lymphoma\*\*\* .

AUTHOR: Luqman Mohammad (Reprint); Hsu Ssucheng J; Ericson Matthew; Klabunde Sha; Kantak Seema

AUTHOR ADDRESS: Inst Biomed Res, Emeryville, CA USA\*\*USA

JOURNAL: Blood 110 (11, Part 1): p162A NOV 16 2007 2007

CONFERENCE/MEETING: 49th Annual Meeting of the American-Society-of-Hematology Atlanta, GA, USA December 08 -11, 2007; 20071208

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

12/3/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

0019597945 BIOSIS NO.: 200700257686

Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin G production in patients with non-hodgkin \*\*\*lymphoma\*\*\* treated with \*\*\*rituximab\*\*\* .

AUTHOR: Nishio Mitsufumi (Reprint); Fujimoto Katsuya; Yamamoto Satoshi; Sakai Toshiya; Kumano Kohki; Obara Masato; Koizumi Kazuki; Mukai Masaya; Sato Norihiro; Koike Takao

AUTHOR ADDRESS: Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan\*\* Japan

JOURNAL: Blood 108 (11, Part 1): p280A NOV 16 2006 2006

CONFERENCE/MEETING: 48th Annual Meeting of the American-Society-of-Hematology Orlando, FL, USA December 09 -12, 2006; 20061209

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

12/3/3 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

0019586341 BIOSIS NO.: 200700246082

Involvement of the Tis11b/Berg36 family in the regulation of B-CLL survival and differentiation.

AUTHOR: Baou Maria (Reprint); Murphy John; Yong Kwee L; Carr Robert; Jewell Andrew P

AUTHOR ADDRESS: Univ London Imperial Coll Sci and Technol, London, UK\*\*UK

JOURNAL: Blood 108 (11, Part 2): p321B NOV 16 2006 2006

CONFERENCE/MEETING: Symposium of the International-Society-of-Molecular-Evolution GUANANACASTE, COSTA RICA January 08 -12, 2001; 20010108

SPONSOR: Int Soc Molec Evolut

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

12/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

19300720 BIOSIS NO.: 200600646115  
Dysregulation of TNF/TNFR superfamily members: A systemic link between  
intra- and extrathyroidal manifestations in Graves' disease  
AUTHOR: Quadbeck B; Stucke M; Eckstein A K; Heise D J; Mann K; Gieseler R K  
(Reprint)  
AUTHOR ADDRESS: LETI Pharma GmbH, Div R and D, Mannesmannstr 4, D-58455  
Witten, Germany\*\*Germany  
AUTHOR E-MAIL ADDRESS: gieseler@leti.de  
JOURNAL: Scandinavian Journal of Immunology 64 (5): p523-530 NOV 2006 2006  
ISSN: 0300-9475  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18839939 BIOSIS NO.: 200600185334  
Humanized anti CD-40 antibody SGN-40 effectively induces cytotoxicity  
against chronic lymphocytic leukemia (CLL) cells through antibody  
mediated cytotoxicity and demonstrates modest biologic evidence of CD40  
activation  
AUTHOR: Gowda Aruna C (Reprint); Zhao Xiaobin B; Cheney Carolyn; Mehter  
Najma; Lozanski Gerard; Lin Thomas S; Guster Sara; Drachman J G;  
Muthusamy Natarajan; Byrd John C  
AUTHOR ADDRESS: Ohio State Univ, Columbus, OH 43210 USA\*\*USA  
JOURNAL: Blood 106 (11, Part 1): p832A NOV 16 2005 2005  
CONFERENCE/MEETING: 47th Annual Meeting of the  
American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005;  
20051210  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18839937 BIOSIS NO.: 200600185332  
A non-internalizing anti-CD40 antibody, CHIR-12.12, blocks CD40L-induced  
cytokine production and mediates greater ADCC than rituximab in  
primary CLL cells  
AUTHOR: Tong Xia (Reprint); Aukerman Sharon Lea; Lin Karen; Aziz Natasha;  
Goldbeck Cheryl; Georgakis Georgios V; Younes Anas; Weng Wen-Kai; O'Brien  
Susan; Wierda William; Jallal Bahija; Luqman Mohammad  
AUTHOR ADDRESS: Chiron Corp, BioPharm Res, Emeryville, CA 94608 USA\*\*USA  
JOURNAL: Blood 106 (11, Part 1): p831A-832A NOV 16 2005 2005  
CONFERENCE/MEETING: 47th Annual Meeting of the  
American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005;  
20051210



SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/7 (Item 7 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18837955 BIOSIS NO.: 200600183350  
Bone marrow mast cells are significantly increased in patients with  
Waldenstrom's Macroglobulinemia, and their number following therapeutic  
intervention is dependent on extent of response  
AUTHOR: Santos Daniel Ditzel (Reprint); Chemaly Mariana Z A; Tournilhac  
Olivier; OConnor Kelly E; Hatjiharissi Evdoxia; Leleu Xavier; Xu Lian;  
Branagan Andrew R; Manning Robert J; Patterson Christopher; Ho Allen W;  
Hunter Zachary R; Tai Yu-Tzu; You James M; Kutok Jeffery L; Anderson  
Kenneth C; Munshi Nikhil; Treon Steven P  
AUTHOR ADDRESS: Dana Farber Canc Inst, Bing Ctr Waldenstroms  
Macroglobulinemia, Boston, MA 02115 USA\*\*USA  
JOURNAL: Blood 106 (11, Part 1): p288A NOV 16 2005 2005  
CONFERENCE/MEETING: 47th Annual Meeting of the  
American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005;  
20051210  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/8 (Item 8 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18837954 BIOSIS NO.: 200600183349  
Establishment of a Waldenstrom's Macroglobulinemia cell line (BCWM.1) with  
productive in vivo engraftment in SCID-hu mice  
AUTHOR: Santos Daniel Ditzel (Reprint); Ho Allen W; Tournilhac Olivier;  
Leleu Xavier; Hatjiharrisi Evdoxia; Xu Lian; Tassone Pierfrancesco; Neri  
Paola; Hunter Zachary; Chemaly Mariana A Z; Branagan Andrew; Manning  
Robert; Patterson Christopher; Adamia Sophia; Kriangkum Jitra; Kutok  
Jeffery L; Pilarski Linda; Anderson Kenneth C; Munshi Nikhil; Treon  
Steven P  
AUTHOR ADDRESS: Dana Farber Canc Inst, Bing Ctr Waldenstroms  
Macroglubulinemia, Boston, MA 02115 USA\*\*USA  
JOURNAL: Blood 106 (11, Part 1): p288A NOV 16 2005 2005  
CONFERENCE/MEETING: 47th Annual Meeting of the  
American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005;  
20051210  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/9 (Item 9 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

18618720 BIOSIS NO.: 200510313220

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40

AUTHOR: Law Che-Leung (Reprint); Gordon Kristine A; Collier John; Klussman Kerry; McEarchern Julie A; Cervený Charles G; Mixan Bruce J; Lee Wyne P; Lin Zhonghau; Valdez Patricia; Wahl Alan F; Grewal Iqbal S

AUTHOR ADDRESS: Seattle Genet Inc, 21823 30th Dr SE, Bothell, WA 98021 USA  
\*\*USA

AUTHOR E-MAIL ADDRESS: claw@seagen.com

JOURNAL: Cancer Research 65 (18): p8331-8338 SEP 15 2005 2005

ISSN: 0008-5472

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

12/3/10 (Item 10 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

18576751 BIOSIS NO.: 200510271251

A fully human anti-CD40 antagonistic antibody, CHIR-12.12, inhibit the proliferation of human B cell non-Hodgkin's lymphoma

AUTHOR: Weng Wen-Kai (Reprint); Tong Xia; Luqman Mohammad; Levy Ronald

AUTHOR ADDRESS: Stanford Univ, Sch Med, Stanford, CA 94305 USA\*\*USA

JOURNAL: Blood 104 (11, Part 1): p896A NOV 16 2004 2004

CONFERENCE/MEETING: 46th Annual Meeting of the

American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004;  
20041204

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

12/3/11 (Item 11 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

18575974 BIOSIS NO.: 200510270474

In vitro activity of a novel fully human anti-CD40 antibody CHIR-12.12 in chronic lymphocytic leukemia: Blockade of CD40 activation and induction of ADCC.

AUTHOR: Tong Xia (Reprint); Georgakis Georgios V; Li Long; Susan O'Brien; Anas Younes; Mohammad Luqman

AUTHOR ADDRESS: Chiron Corp, Res and Dev, Emeryville, CA 94608 USA\*\*USA

JOURNAL: Blood 104 (11, Part 1): p686A NOV 16 2004 2004

CONFERENCE/MEETING: 46th Annual Meeting of the

American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004;  
20041204

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

12/3/12 (Item 12 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18575884 BIOSIS NO.: 200510270384

A fully human antagonist anti-CD40 antibody triggers significant antitumor activity against human multiple myeloma

AUTHOR: Tai Yu-Tzu (Reprint); Li Xian-Feng; Tong Xia; Catley Laurence; Santos Daniel; Tournilhac Olivier; Schlossman Robert; Richardson Paul; Munshi Nikhil C; Luqman Mohammad; Anderson Kenneth C

AUTHOR ADDRESS: Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA\*\*USA

JOURNAL: Blood 104 (11, Part 1): p663A-664A NOV 16 2004 2004

CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004; 20041204

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

12/3/13 (Item 13 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18574566 BIOSIS NO.: 200510269066

Generation of anti-leukemia reactive T-cells by costimulation with established B-ALL cell lines expressing costimulatory molecules

AUTHOR: Yan Ying (Reprint); Steiherz Peter; Ruan Jianda; Chen Yibang; Abhyankar Sunil; Guan Xiuqin; Williams Casey; Belt Robert; McGuirk Joseph  
AUTHOR ADDRESS: UMKC, Canc Inst Kansas City, Sch Med, Leukemia Lymphoma Program, Kansas City, MO USA\*\*USA

JOURNAL: Blood 104 (11, Part 1): p311A NOV 16 2004 2004

CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004; 20041204

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

12/3/14 (Item 14 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18572914 BIOSIS NO.: 200510267414

Regulation of Berg-36 gene expression by survival and apoptotic stimuli in B-chronic lymphocytic leukaemia cells.

AUTHOR: Jewell Andrew P (Reprint); Baou Maria; Yong Kwee L; Carr Robert; Murphy John

AUTHOR ADDRESS: Kingston Univ, Kingston upon Thames KT1 2EE, Surrey, UK\*\*UK

JOURNAL: Blood 104 (11, Part 2): p275B NOV 16 2004 2004

CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004; 20041204

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract  
LANGUAGE: English

12/3/15 (Item 15 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18442500 BIOSIS NO.: 200510137000  
Mitogen induced activation, proliferation and surface antigen expression  
patterns in unmutated and hypermutated chronic lymphocytic leukemia  
cells  
AUTHOR: Vilpo Juhani (Reprint); Tobin Gerard; Hulkkonen Janne; Hurme Mikko;  
Thunberg Ulf; Sundstrom Christer; Vilpo Leena; Rosenquist Richard  
AUTHOR ADDRESS: PACiuksenkatu 6 A 4, Helsinki 00290, Finland\*\*Finland  
AUTHOR E-MAIL ADDRESS: medivil@kolumbus.fi  
JOURNAL: European Journal of Haematology 75 (1): p34-40 JUL 05 2005  
ISSN: 0902-4441  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/16 (Item 16 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18128719 BIOSIS NO.: 200500035784  
Improved access to CD20 following B cell receptor cross-linking at  
Burkitt's lymphoma cell surfaces  
AUTHOR: Holder Michelle J; Chamba Anita; Hardie Debbie L; Deans Julie P;  
Gordon John (Reprint)  
AUTHOR ADDRESS: Sch MedMRCCTR Immune Regulat, Univ Birmingham, Vincent Dr,  
Birmingham, W Midlands, B15 2TT, UK\*\*UK  
AUTHOR E-MAIL ADDRESS: j.gordan@bham.ac.uk  
JOURNAL: Leukemia Research 28 (11): p1197-1202 November 2004 2004  
MEDIUM: print  
ISSN: 0145-2126 \_(ISSN print)  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/17 (Item 17 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

17781139 BIOSIS NO.: 200400147800  
CD40 ligand (CD40L) stimulation prior to conventional  
cytogenetic analysis reveals a high frequency of complex karyotype  
aberrations in patients with CLL: A comparison with clinical and  
prognostic features of 92 patients.  
AUTHOR: Mayr Christine (Reprint); Schoch Claudia (Reprint); Buhmann Raymund  
(Reprint); Wendtner Clemens (Reprint); Hallek Michael (Reprint)  
AUTHOR ADDRESS: Department of Internal Medicine, Klinikum Grosshadern,  
Ludwig-Maximilians University, Munich, Germany\*\*Germany  
JOURNAL: Blood 102 (11): p669a November 16, 2003 2003  
MEDIUM: print  
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of  
Hematology San Diego, CA, USA December 06-09, 2003; 20031206  
SPONSOR: American Society of Hematology

ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/18 (Item 18 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

17781046 BIOSIS NO.: 200400147707  
Comparative efficacy of Rituximab and a fully human anti-CD40  
antagonist antibody in in vitro and in xenograft \*\*\*lymphoma\*\*\* models.  
AUTHOR: Long Li (Reprint); Tong Xia (Reprint); Patawaran Montesa (Reprint);  
Luqman Mohammad (Reprint)  
AUTHOR ADDRESS: Research, Chiron Corporation, Emeryville, CA, USA\*\*USA  
JOURNAL: Blood 102 (11): p646a November 16, 2003 2003  
MEDIUM: print  
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of  
Hematology San Diego, CA, USA December 06-09, 2003; 20031206  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/19 (Item 19 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

17780221 BIOSIS NO.: 200400146882  
Induction of an immunogenic and apoptotic phenotype in B chronic  
lymphocytic leukemia (B-CLL) cells by immunostimulatory PyNTTTTGT  
oligodeoxynucleotides (ODN).  
AUTHOR: Dupont Juan (Reprint); Flo Juan; Zorzopulos Jorge; Riveros Dardo  
(Reprint); Lopez Ricardo; Garay Guy (Reprint); Cacchione Roberto  
(Reprint)  
AUTHOR ADDRESS: Hematology, CEMIC, Buenos Aires, Argentina\*\*Argentina  
JOURNAL: Blood 102 (11): p429a-430a November 16, 2003 2003  
MEDIUM: print  
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of  
Hematology San Diego, CA, USA December 06-09, 2003; 20031206  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/20 (Item 20 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

17766571 BIOSIS NO.: 200400133925  
Analysis of tumor-specific T cell immune response in follicular  
non-Hodgkin's \*\*\*lymphoma\*\*\* patients treated with \*\*\*rituximab\*\*\* .  
AUTHOR: Weng Wen-Kai (Reprint); Levy Ronald (Reprint)  
AUTHOR ADDRESS: Medicine/Oncology, Stanford University School of Medicine,  
Stanford, CA, USA\*\*USA  
JOURNAL: Blood 102 (11): p391a November 16, 2003 2003

MEDIUM: print  
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/21 (Item 21 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

17380281 BIOSIS NO.: 200300337024  
CD40 Ligation Induces Expression of Antigen Processing and Presentation Genes in Chronic Lymphocytic \*\*\*Leukemia\*\*\* Cells.  
AUTHOR: Kohlmann Alexander (Reprint); Dicker Frank (Reprint); Moritz Dirk R (Reprint); Maass Gerd (Reprint); Seeber Stefan (Reprint); Haferlach Torsten (Reprint); Kipps Thomas J (Reprint)  
AUTHOR ADDRESS: Pharma Research, Roche Diagnostics GmbH, Penzberg, Germany  
\*\*Germany  
JOURNAL: Blood 100 (11): pAbstract No. 2326 November 16, 2002 2002  
MEDIUM: print  
CONFERENCE/MEETING: 44th Annual Meeting of the American Society of Hematology Philadelphia, PA, USA December 06-10, 2002; 20021206  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/22 (Item 22 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

16647704 BIOSIS NO.: 200200241215  
Human anti-CD40 antagonistic antibodies inhibit the proliferation of human B cell non-Hodgkin's lymphoma  
AUTHOR: Weng Wen-Kai (Reprint); Wang Changyu; Chu Keting; Levy Ronald (Reprint)  
AUTHOR ADDRESS: Medicine/Oncology, Stanford University, Stanford, CA, USA\*\*  
USA  
JOURNAL: Blood 98 (11 Part 1): p466a November 16, 2001 2001  
MEDIUM: print  
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/23 (Item 23 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

16140018 BIOSIS NO.: 200100311857  
Generation of polyclonal plasma cells from peripheral blood B cells: How to

get a normal counterpart of malignant plasma cells  
AUTHOR: Tarte Karin (Reprint); Fiol Genevieve (Reprint); Legouffe Eric;  
Rossi Jean-Francois; Klein Bernard (Reprint)  
AUTHOR ADDRESS: UTC, CHU St Eloi, Montpellier, France\*\*France  
JOURNAL: Blood 96 (11 Part 1): p514a November 16, 2000 2000  
MEDIUM: print  
CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of  
Hematology San Francisco, California, USA December 01-05, 2000; 20001201  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/24 (Item 24 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

15977603 BIOSIS NO.: 200100149442  
CpG DNA increases primary malignant B cell expression of costimulatory  
molecules and target antigens  
AUTHOR: Jahrsdorfer Bernd; Hartmann Gunther; Racila Emil; Jackson Wallen;  
Muhlenhoff Lars; Meinhardt Gerold; Endres Stefan; Link Brian K; Krieg  
Arthur M; Weiner George J (Reprint)  
AUTHOR ADDRESS: University of Iowa Cancer Center, University of Iowa, 5970Z  
JPP, Iowa City, IA, 52242, USA\*\*USA  
JOURNAL: Journal of Leukocyte Biology 69 (1): p81-88 January, 2001 2001  
MEDIUM: print  
ISSN: 0741-5400  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/25 (Item 25 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

15701561 BIOSIS NO.: 200000419874  
A flow cytometric immune function assay for human peripheral blood  
dendritic cells  
AUTHOR: Willmann Kerstin (Reprint); Dunne John F  
AUTHOR ADDRESS: 2350 Qume Drive, San Jose, CA, 95131, USA\*\*USA  
JOURNAL: Journal of Leukocyte Biology 67 (4): p536-544 April, 2000 2000  
MEDIUM: print  
ISSN: 0741-5400  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/26 (Item 26 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

15321415 BIOSIS NO.: 200000039728  
Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's  
disease  
AUTHOR: Battaglia Edda; Biancone Luigi; Resegotti Andrea; Emanuelli Giorgio  
; Fronda Gian Ruggero; Camussi Giovanni (Reprint)

AUTHOR ADDRESS: Cattedra di Nefrologia, Dipartimento di Medicina Interna,  
Universita di Torino, Corso Dogliotti 14, 10126, Torino, Italy\*\*Italy  
JOURNAL: American Journal of Gastroenterology 94 (11): p3279-3284 Nov.,  
1999 1999  
MEDIUM: print  
ISSN: 0002-9270  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/27 (Item 27 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

14954687 BIOSIS NO.: 199900214347  
Expression of CD40/CD40 ligand and Bcl-2 family proteins in labial salivary  
glands of patients with Sjogren's syndrome  
AUTHOR: Nakamura Hideki; Kawakami Atsushi; Tominaga Masahiro; Migita  
Kiyoshi; Kawabe Yojiro; Nakamura Tatsufumi; Eguchi Katsumi (Reprint)  
AUTHOR ADDRESS: The First Department of Internal Medicine, Nagasaki  
University School of Medicine, 1-7-1 Sakamoto, Nagasaki City, 852-8501,  
Japan\*\*Japan  
JOURNAL: Laboratory Investigation 79 (3): p261-269 March, 1999 1999  
MEDIUM: print  
ISSN: 0023-6837  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/28 (Item 28 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

14434691 BIOSIS NO.: 199800228938  
Chronic lymphocytic leukemia B cells can express CD40 ligand and  
demonstrate T-cell type costimulatory capacity  
AUTHOR: Schattner Elaine J (Reprint); Mascarenhas John; Reyfman Inna; Koshy  
Mary; Woo Caroline; Friedman Steven M; Crow Mary K  
AUTHOR ADDRESS: Room C-640, Cornell Univ. Med. Coll., 1300 York Ave., New  
York, NY 10021, USA\*\*USA  
JOURNAL: Blood 91 (8): p2689-2697 April 15, 1998 1998  
MEDIUM: print  
ISSN: 0006-4971  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/29 (Item 29 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

13701505 BIOSIS NO.: 199799335565  
Increased inhibition of proliferation of human B cell lymphomas  
following ligation of CD40, and either CD19, CD20, CD95 or  
surface immunoglobulin  
AUTHOR: Benoit Nicole E; Wade William F (Reprint)  
AUTHOR ADDRESS: Dep. Microbiol., Dartmouth Med. Sch., Lebanon, NH 03756,  
USA\*\*USA



JOURNAL: Immunopharmacology 35 (2): p129-139 1996 1996  
ISSN: 0162-3109  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/30 (Item 30 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

13374833 BIOSIS NO.: 199699008893  
CD20 and CD40 mediated mitogenic responses in B-lineage acute  
lymphoblastic leukaemia  
AUTHOR: Smiers Frans J; Van Paassen Marleen; Hahlen Karel; Lowenberg Bob;  
Touw Ivo P (Reprint)  
AUTHOR ADDRESS: Inst. Haematol., Erasmus Univ. Rotterdam, PO Box 1738, 3000  
Dr Rotterdam, Netherlands\*\*Netherlands  
JOURNAL: British Journal of Haematology 93 (1): p125-130 1996 1996  
ISSN: 0007-1048  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/31 (Item 31 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

13000597 BIOSIS NO.: 199598468430  
Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell  
lymphomagenesis in severe combined immune deficient mice given  
human peripheral blood lymphocytes  
AUTHOR: Murphy William J (Reprint); Funakoshi Satoshi; Beckwith Margaret;  
Rushing Susan E; Conley Denise K; Armitage Richard J; Fanslow William C;  
Rager Helen C; Taub Dennis D; Ruscetti Francis W; Longo Dan L  
AUTHOR ADDRESS: Biol. Carcinogenesis and Dev. Program, Program Resources  
Inc./DynCorp, NCI-FCRDC, Build. 567, Room 141, Frederick, MD 21702-1201,  
USA\*\*USA  
JOURNAL: Blood 86 (5): p1946-1953 1995 1995  
ISSN: 0006-4971  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/32 (Item 32 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

12064964 BIOSIS NO.: 199497086249  
Differential expression of surface antigens on activated endothelium  
AUTHOR: Favaloro Emmanuel J  
AUTHOR ADDRESS: Dep. Haematology, Inst. Clinical Pathology Med. Res.,  
Westmead Hosp., Westmead, NSW 2145, Australia\*\*Australia  
JOURNAL: Immunology and Cell Biology 71 (6): p571-581 1993 1993  
ISSN: 0818-9641  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/33 (Item 33 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

12004094 BIOSIS NO.: 199497025379  
Characterization of a cell surface glycoprotein IPO-3, expressed on  
activated human B and T lymphocytes  
AUTHOR: Sidorenko Svetlana P; Clark Edward A  
AUTHOR ADDRESS: Regional Primate Res. Cent. SJ-50, Univ. Washington,  
Seattle, WA 98195, USA\*\*USA  
JOURNAL: Journal of Immunology 151 (9): p4614-4624 1993 1993  
ISSN: 0022-1767  
DOCUMENT TYPE: Article; Literature Review  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/34 (Item 34 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

11737239 BIOSIS NO.: 199395039505  
The human T cell antigen gp39, a member of the TNF gene family, is a ligand  
for the CD40 receptor: Expression of a soluble form of gp39 with B  
cell co-stimulatory activity  
AUTHOR: Hollenbaugh Diane (Reprint); Grosmaire Laura S (Reprint); Kullas  
Christopher D (Reprint); Chalupny N Jan (Reprint); Braesch-Andersen Sten;  
Stamenkovic Randolph J Vv Noelleen; Ledbetter Jeffrey A (Reprint); Aruffo  
Alejandro (Reprint)  
AUTHOR ADDRESS: Bristol-Myers Squibb Pharmaceutical Research Inst.,  
Seattle, Wash. 98121, USA\*\*USA  
JOURNAL: EMBO (European Molecular Biology Organization) Journal 11 (12): p  
4313-4321 1992  
ISSN: 0261-4189  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/35 (Item 35 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

11307186 BIOSIS NO.: 199294009027  
IL-4 INDUCES CONFORMATIONAL CHANGE OF CD20 ANTIGEN VIA A PROTEIN  
KINASE C-INDEPENDENT PATHWAY ANTAGONISTIC EFFECT OF ANTI-CD40 MONOCLONAL  
ANTIBODY  
AUTHOR: DANCESCU M (Reprint); WU C; RUBIO M; DELESSESSE G; SARFATI M  
AUTHOR ADDRESS: ALLERGY RES LAB, NOTRE-DAME HOSP RES CENT, 1560 SHERBROOKE  
ST EAST, MONTREAL, QUE H2L 4M1\*\*CANADA  
JOURNAL: Journal of Immunology 148 (8): p2411-2416 1992  
ISSN: 0022-1767  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

12/3/36 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0082010530 EMBASE No: 2007444915

CD40 expression identifies a prognostically favourable subgroup of  
diffuse large B-cell lymphoma

Linderoth J.; Ehinger M.; Jerkeman M.; Bendahl P.-O.; Akerman M.;  
Berglund M.; Enblad G.; Erlanson M.; Roos G.; Cavallin-Stahl E.

Department of Oncology, Institution of Clinical Sciences, Lund University  
Hospital, Lund, Sweden

CORRESP. AUTHOR/AFFIL: Linderoth J.: Department of Oncology, Institution  
of Clinical Sciences, Lund University Hospital, Lund, Sweden

Leukemia and Lymphoma ( Leuk. Lymphoma ) (United Kingdom) September 1,  
2007, 48/9 (1774-1779)

CODEN: LELYE ISSN: 1042-8194 eISSN: 1029-2403

PUBLISHER ITEM IDENTIFIER: 781803128

DOI: 10.1080/10428190701494520

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 26

12/3/37 (Item 2 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0081529562 EMBASE No: 2006593143

Cancer: Novel therapeutic strategies that exploit the TNF-related  
apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway

Cretny E.; Takeda K.; Smyth M.J.

Cancer Immunology Program, Trescowthick Research Laboratories, Peter  
MacCallum Cancer Centre, East Melbourne, Vic. 3002, Australia

AUTHOR EMAIL: mark.smyth@petermac.org

CORRESP. AUTHOR/AFFIL: Smyth M.J.: Cancer Immunology Program,  
Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East  
Melbourne, Vic. 3002, Australia

CORRESP. AUTHOR EMAIL: mark.smyth@petermac.org

International Journal of Biochemistry and Cell Biology ( Int. J. Biochem.  
Cell Biol. ) (United Kingdom) January 15, 2007, 39/2 (280-286)

CODEN: IJBBF ISSN: 1357-2725

PUBLISHER ITEM IDENTIFIER: S1357272506002792

DOI: 10.1016/j.biocel.2006.10.005

DOCUMENT TYPE: Journal; Short Survey RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 44

12/3/38 (Item 3 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0081342922 EMBASE No: 2006405477

Can drug effects help elucidate the pathogenesis of SLE?

Fang C.J.; Hahn B.H.; Furst D.E.

UCLA Medical School, Rheumatology Division, 1000 Veteran Avenue, Los  
Angeles, CA 98101, United States

AUTHOR EMAIL: defurst@mednet.ucla.edu

CORRESP. AUTHOR/AFFIL: Furst D.E.: UCLA Medical School, Rheumatology  
Division, 1000 Veteran Avenue, Los Angeles, CA 98101, United States

CORRESP. AUTHOR EMAIL: defurst@mednet.ucla.edu

Current Rheumatology Reviews ( Curr. Rheumatol. Rev. ) (Netherlands)  
August 1, 2006, 2/3 (233-244)  
ISSN: 1573-3971  
DOI: 10.2174/157339706778019629  
URL:

<http://www.ingentaconnect.com/content/ben/crr/2006/00000002/00000003/art00003>

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 112

12/3/39 (Item 4 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080759169 EMBASE No: 2005403690  
New treatments for SLE: Cell-depleting and anti-cytokine therapies  
Anolik J.H.; Aringer M.  
Allergy, Immunology and Rheumatology Unit, Department of Medicine,  
University of Rochester School of Medicine and Dentistry, Rochester, NY  
14642, United States  
AUTHOR EMAIL: jennifer; anolik@urmc.rochester.edu  
CORRESP. AUTHOR/AFFIL: Anolik J.H.: Allergy, Immunology and Rheumatology  
Unit, Department of Medicine, University of Rochester School of Medicine  
and Dentistry, Rochester, NY 14642, United States  
CORRESP. AUTHOR EMAIL: jennifer; anolik@urmc.rochester.edu

Best Practice and Research in Clinical Rheumatology ( Best Pract. Res.  
Clin. Rheumatol. ) (United Kingdom) October 1, 2005, 19/5 SPEC. ISS.  
(859-878)  
CODEN: BPRCC ISSN: 1521-6942  
PUBLISHER ITEM IDENTIFIER: S1521694205000707  
DOI: 10.1016/j.berh.2005.05.006  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 121

12/3/40 (Item 5 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080467107 EMBASE No: 2005111263  
Fc receptor targeting in the treatment of allergy, autoimmune diseases  
and cancer  
Nakamura A.; Akiyama K.; Takai T.  
Tohoku University, Dept. of Experimental Immunology, Inst. of Development  
ageing/Cancer, Seiryo 4-1, Sendai 980-8575, Japan  
AUTHOR EMAIL: aki@idac.tohoku.ac.jp  
CORRESP. AUTHOR/AFFIL: Nakamura A.: Tohoku University, Dept. of  
Experimental Immunology, Inst. of Development ageing/Cancer, Seiryo 4-1,  
Sendai 980-8575, Japan  
CORRESP. AUTHOR EMAIL: aki@idac.tohoku.ac.jp

Expert Opinion on Therapeutic Targets ( Expert Opin. Ther. Targets ) (  
United Kingdom) February 1, 2005, 9/1 (169-190)  
CODEN: EOTTA ISSN: 1472-8222  
DOI: 10.1517/14728222.9.1.169  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 189

12/3/41 (Item 6 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0079921581 EMBASE No: 2004106604  
Selective depletion of activated T cells: The CD40L-specific antibody  
experience  
Hargreaves R.E.G.; Monk N.J.; Jurcevic S.  
Dept. of Nephrology and Transplant., Guy'S, King's St. Thomas' Med. Sch.,  
Guy's Hospital, London, SE1 9RT, United Kingdom  
AUTHOR EMAIL: stipo.jurcevic@kcl.ac.uk  
CORRESP. AUTHOR/AFFIL: Jurcevic S.: Dept. of Nephrology and Transplant.,  
Guy'S, King's St. Thomas' Med. Sch., Guy's Hospital, London, SE1 9RT,  
United Kingdom  
CORRESP. AUTHOR EMAIL: stipo.jurcevic@kcl.ac.uk

Trends in Molecular Medicine ( Trends Mol. Med. ) (United Kingdom) March  
1, 2004, 10/3 (130-135)  
CODEN: TMMRC ISSN: 1471-4914  
PUBLISHER ITEM IDENTIFIER: S1471491404000267  
DOI: 10.1016/j.molmed.2004.01.009  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 43

12/3/42 (Item 7 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0079891356 EMBASE No: 2004076254  
Indolent B-cell malignancies: Immune recognition and antiself  
Gribben J.G.  
Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Avenue,  
Boston, MA 02115, United States  
AUTHOR EMAIL: john; gribben@dfci.harvard.edu  
CORRESP. AUTHOR/AFFIL: Gribben J.G.: Dana Farber Cancer Institute,  
Harvard Medical School, 44 Binney Avenue, Boston, MA 02115, United States  
CORRESP. AUTHOR EMAIL: john; gribben@dfci.harvard.edu

Leukemia and Lymphoma ( Leuk. Lymphoma ) (United Kingdom) December 1,  
2003, 44/SUPPL. 3 (S77-S83)  
CODEN: LELYE ISSN: 1042-8194  
DOI: 10.1080/10428190310001623739  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 56

12/3/43 (Item 8 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0078999883 EMBASE No: 2002163578  
16th Annual Scientific Meeting of the Society for Biological Therapy  
Dillman R.O.; Dillman J.B.  
Clin. and Laboratory Cancer Research, Hoag Cancer Center, Bldg 41, 1 Hoag  
Drive, Newport Beach, CA 92658, United States

CORRESP. AUTHOR/AFFIL: Dillman R.O.: Clin. and Laboratory Cancer Research, Hoag Cancer Center, Bldg 41, 1 Hoag Drive, Newport Beach, CA 92658, United States

CORRESP. AUTHOR EMAIL: rdillman@hoaghospital.org

Expert Opinion on Biological Therapy ( Expert Opin. Biol. Ther. ) (United Kingdom) May 21, 2002, 2/2 (223-227)

CODEN: EOBTA ISSN: 1471-2598

DOI: 10.1517/14712598.2.2.223

DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

12/3/44 (Item 9 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0078325759 EMBASE No: 2000375362

Immunotherapeutic strategies for the treatment of plasma cell malignancies

Treon S.P.; Raje N.; Anderson K.C.

Division of Hematologic Malignancies, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, United States

CORRESP. AUTHOR/AFFIL: Anderson K.C.: Division of Hematologic Malignancies, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, United States

Seminars in Oncology ( Semin. Oncol. ) (United States) November 13, 2000 , 27/5 (598-613)

CODEN: SOLGA ISSN: 0093-7754

DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 156

12/3/45 (Item 10 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0078280176 EMBASE No: 2000329766

Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma

Chaperot L.; Chokri M.; Jacob M.-C.; Drillat P.; Garban F.; Egelhofer H.; Molens J.-P.; Sotto J.-J.; Bensa J.-C.; Plumas J.

Department of Cell Therapy, ETS de l'Isere et de la Savoie, BP 35, F-38701 La Tronche Cedex, France

CORRESP. AUTHOR/AFFIL: Chaperot L.: Department of Cell Therapy, ETS de l'Isere et de la Savoie, BP 35, F-38701 La Tronche Cedex, France

Leukemia ( Leukemia ) (United Kingdom) October 2, 2000, 14/9 (1667-1677)

CODEN: LEUKE ISSN: 0887-6924

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 49

12/3/46 (Item 11 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0076676499 EMBASE No: 1996352908

Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and iehter CD19, CD20, CD95 or surface immunoglobulin

Benoit N.E.; Wade W.F.

Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756, United States

AUTHOR EMAIL: william.wade@dartmouth.edu

CORRESP. AUTHOR/AFFIL: Wade W.F.: Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756, United States

Immunopharmacology ( IMMUNOPHARMACOLOGY ) (Netherlands) November 1, 1996 , 35/2 (129-139)

CODEN: IMMUD ISSN: 0162-3109

PUBLISHER ITEM IDENTIFIER: S0162310996001385

DOI: 10.1016/S0162-3109(96)00138-5

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 33

12/3/47 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

16916665 PMID: 16525683

Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous \*\*\*cancer\*\*\* cells in vitro.

Tanaka Tetsuji; Bai Tao; Yukawa Kazunori; Umesaki Naohiko

Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama 641-0012, Japan. tetanaka@wakayama-med.ac.jp

Oncology reports (Greece) Apr 2006, 15 (4) p939-47, ISSN 1021-335X --Print Journal Code: 9422756

Publishing Model Print

Document type: Journal Article; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

12/3/48 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

14671788 PMID: 12072193

CM1 ligation initiates apoptosis in a caspase 8-dependent manner in Ramos cells and in a mitochondria-controlled manner in Raji cells.

Kim Daejin; Hur Dae Young; Kim Yeong Seok; Lee Kyungmi; Lee Youngseon; Cho Daeho; Kang Jae Seung; Kim Young-in; Hahm Eunsil; Yang Yoolhee; Yoon Suyoung; Kim Seonghan; Lee Won Bok; Park Hae Young; Kim Yoon Berm; Hwang Young-il; Chang Ka Y; Lee Wang Jae

Department of Anatomy, Seoul National University, College of Medicine and Institute of Allergy and Clinical Immunology, Medical Research Center, Seoul National University, Seoul, South Korea.

Human immunology (United States) Jul 2002, 63 (7) p576-87, ISSN 0198-8859--Print Journal Code: 8010936

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

12/3/49 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

148512812 CA: 148(23)512812w PATENT  
Base-modified RNA for increasing protein expression  
INVENTOR(AUTHOR): Hoerr, Ingmar; Von der Muelbe, Florian  
LOCATION: Germany,  
ASSIGNEE: Curevac G.m.b.H.  
PATENT: PCT International ; WO 200852770 A2 DATE: 20080508  
APPLICATION: WO 2007EP9469 (20071031) \*DE 1006051516 (20061031)  
PAGES: 105pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-000/A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;  
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI;  
GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP;  
KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY;  
MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK;  
SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ DESIGNATED REGIONAL: AT; BE; BG; CH  
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;  
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;  
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

12/3/50 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

147110188 CA: 147(6)110188d PATENT  
Use of stimulatory anti-CD40 antibodies in the treatment of diseases  
associated with aberrant CD40 presentation on cell surfaces  
INVENTOR(AUTHOR): Drachman, Jonathan; Law, Che-Leung; Lewis, Tim  
LOCATION: USA  
ASSIGNEE: Seattle Genetics, Inc.  
PATENT: PCT International ; WO 200775326 A2 DATE: 20070705  
APPLICATION: WO 2006US47308 (20061211) \*US 2005PV749246 (20051209) \*US  
2006PV811353 (20060605) \*US 2006PV811301 (20060605) \*US 2006PV847234  
(20060925)  
PAGES: 125pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
IPCR/8 + Level Value Position Status Version Action Source Office:  
A61K-0039/395 A I F B 20060101 H US  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ;  
LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA;  
NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM;  
SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH  
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;  
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;  
MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM;  
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

12/3/51 (Item 3 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.



144231465 CA: 144(13)231465p PATENT  
 Humanized antibodies with Man3GlcNAc2 modification to increase  
 FcγRIII receptor binding and ADCC for therapeutic use  
 INVENTOR(AUTHOR): Gerngross, Tillman U.; Li, Huijuan; Wildt, Stefan  
 LOCATION: USA  
 PATENT: U.S. Pat. Appl. Publ. ; US 20060034829 A1 DATE: 20060216  
 APPLICATION: US 2005187079 (20050721) \*US 2001PV344169 (20011227) \*WO  
 2002US41510 (20021224) \*US 2004PV589913 (20040721) \*US 2004PV589937  
 (20040721) \*US 2005500240 (20050323)  
 PAGES: 47 pp., Cont.-in-part of U.S. Ser. No. 500,240. CODEN: USXXCO  
 LANGUAGE: English  
 PATENT CLASSIFICATIONS:  
 CLASS: 424130100  
 IPCR/8 + Level Value Position Status Version Action Source Office:  
 C07K-0016/28 A I F B 20060101 20060216 H US  
 C07H-0021/04 A I L B 20060101 20060216 H US  
 C12P-0021/06 A I L B 20060101 20060216 H US  
 A61K-0039/395 A I L B 20060101 20060216 H US  
 C12N-0005/06 A I L B 20060101 20060216 H US

12/3/52 (Item 4 from file: 399)  
 DIALOG(R)File 399:CA SEARCH(R)  
 (c) 2008 American Chemical Society. All rts. reserv.

144005405 CA: 144(1)5405n PATENT  
 Antibody glycosylation variants having increased antibody-dependent  
 cellular cytotoxicity  
 INVENTOR(AUTHOR): Umana, Pablo; Jean-Mairet, Joel; Bailey, James E.  
 LOCATION: Switz.  
 ASSIGNEE: Glycart Biotechnology AG  
 PATENT: U.S. Pat. Appl. Publ. ; US 20050272128 A1 DATE: 20051208  
 APPLICATION: US 2005199232 (20050809) \*US 2002211554 (20020805) \*US  
 2003633697 (20030805)  
 PAGES: 28 pp., Cont.-in-part of U.S. Ser. No. 633,697. CODEN: USXXCO  
 LANGUAGE: English  
 PATENT CLASSIFICATIONS:  
 CLASS: 435069100; C07K-016/28A; C07H-021/04B; C12P-021/06B;  
 C12N-005/06B

12/3/53 (Item 5 from file: 399)  
 DIALOG(R)File 399:CA SEARCH(R)  
 (c) 2008 American Chemical Society. All rts. reserv.

143241996 CA: 143(14)241996f PATENT  
 Methods using a toll-like receptor-2 (TLR2) agonist for treating  
 immunopathological disorders  
 INVENTOR(AUTHOR): Raz, Eyal; Redecke, Vanessa Doreen; Horner, Anthony A.  
 LOCATION: USA  
 ASSIGNEE: The Regents of the University of California  
 PATENT: PCT International ; WO 200579419 A2 DATE: 20050901  
 APPLICATION: WO 2005US4895 (20050216) \*US 2004PV545353 (20040217)  
 PAGES: 50 pp. CODEN: PIXXD2 LANGUAGE: English  
 PATENT CLASSIFICATIONS:  
 CLASS: A61K-000/A  
 DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
 BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
 GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
 LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;  
 PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;

UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ  
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;  
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU;  
MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG

12/3/54 (Item 6 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

143053027 CA: 143(4)53027s JOURNAL  
B-Cell Lymphomas Differ in their Responsiveness to CpG  
Oligodeoxynucleotides  
AUTHOR(S): Jahrsdorfer, Bernd; Muehlenhoff, Lars; Blackwell, Sue E.;  
Wagner, Moritz; Poeck, Hendrik; Hartmann, Evelyn; Jox, Ralf; Giese, Thomas;  
Emmerich, Bertold; Endres, Stefan; Weiner, George J.; Hartmann, Gunther  
LOCATION: Division of Clinical Pharmacology, University of Munich, Munich  
, Germany,  
JOURNAL: Clin. Cancer Res. (Clinical Cancer Research) DATE: 2005  
VOLUME: 11 NUMBER: 4 PAGES: 1490-1499 CODEN: CCREF4 ISSN: 1078-0432  
LANGUAGE: English PUBLISHER: American Association for Cancer Research

12/3/55 (Item 7 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

142273998 CA: 142(15)273998d PATENT  
Treatment for CD5+ B cell lymphoma  
INVENTOR(AUTHOR): Miller, Richard L.; Spaner, David E.  
LOCATION: USA  
ASSIGNEE: 3M Innovative Properties Company  
PATENT: U.S. Pat. Appl. Publ. ; US 20050054665 A1 DATE: 20050310  
APPLICATION: US 2004933594 (20040903) \*US 2003PV500478 (20030905) \*US  
2004PV561440 (20040412)  
PAGES: 25 pp. CODEN: USXXCO LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: 514292000; A61K-031/4745A

12/3/56 (Item 8 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

141172878 CA: 141(11)172878p PATENT  
Engineering of glycosylation profile of antibody Fc region to increase Fc  
receptor binding affinity and effector function for treating cancer  
INVENTOR(AUTHOR): Umana, Pablo; Bruenker, Peter; Ferrara, Claudia; Suter,  
Tobias  
LOCATION: Switz.  
ASSIGNEE: Glycart Biotechnology Ag  
PATENT: PCT International ; WO 200465540 A2 DATE: 20040805  
APPLICATION: WO 2004IB844 (20040122) \*US PV441307 (20030122) \*US PV491254  
(20030731) \*US PV495142 (20030815)  
PAGES: 231 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: C12N-000/A  
DESIGNATED COUNTRIES: AE; AE; AG; AL; AL; AM; AM; AM; AT; AT; AU; AZ; AZ;  
BA; BB; BG; BG; BR; BR; BW; BY; BY; BZ; BZ; CA; CH; CN; CN; CO; CO; CR; CR;  
CU; CU; CZ; CZ; DE; DE; DK; DK; DM; DZ; EC; EC; EE; EE; EG; ES; ES; FI; FI;

GB; GD; GE; GE; GH; GM; HR; HR; HU; HU; ID; IL; IN; IS; JP; JP; KE; KE; KG; KG; KP; KP; KP; KR; KR; KZ; KZ; KZ; LC; LK; LR; LS; LS; LT; LU; LV; MA; MD; MD; MG; MK; MN; MW; MX; MX; MZ; MZ; NA; NI

12/3/57 (Item 9 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

138152272 CA: 138(11)152272w PATENT  
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity  
INVENTOR(AUTHOR): Jean-Mairet, Joel; Umana, Pablo; Bailey, James E.  
LOCATION: Switz.  
ASSIGNEE: Glycart Biotechnology AG; Bailey, Sean  
PATENT: PCT International ; WO 200311878 A2 DATE: 20030213  
APPLICATION: WO 2002US24739 (20020805) \*US PV309516 (20010803)  
PAGES: 68 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: C07H-000/A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG  
? t s12/7/28,30,42,44,45

12/7/28 (Item 28 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

14434691 BIOSIS NO.: 199800228938  
Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity  
AUTHOR: Schattner Elaine J (Reprint); Mascarenhas John; Reyfman Inna; Koshy Mary; Woo Caroline; Friedman Steven M; Crow Mary K  
AUTHOR ADDRESS: Room C-640, Cornell Univ. Med. Coll., 1300 York Ave., New York, NY 10021, USA\*\*USA  
JOURNAL: Blood 91 (8): p2689-2697 April 15, 1998 1998  
MEDIUM: print  
ISSN: 0006-4971  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: Chronic lymphocytic leukemia (CLL) is characterized by a clonal expansion of CD5+ B cells in the peripheral blood. Associated immune aberrations include abnormal Th-cell function and pathogenic autoantibodies. Under most circumstances, CLL B cells do not proliferate in culture and express a limited repertoire of surface antigens, including CD19, \*\*\*CD20\*\*\*, CD23, CD27, CD40, and CD70. In this report, we demonstrate that freshly isolated B cells from a subset of CLL cases constitutively express CD40 ligand (CD40L, CD154), a member of the tumor necrosis factor family which is normally expressed by activated CD4+ T cells and mediates T-cell-dependent B-cell proliferation and antibody production. The degree of CD40L expression varied considerably among the CLL cases examined. CD40L was detected in purified

CLL B cells by immunofluorescence flow cytometry, by RT-PCR, and by immunoprecipitation. To demonstrate that \*\*\*CD40L\*\*\* in the CLL B cells is functional, we used irradiated CLL cells to stimulate IgG production by target, nonmalignant 8 cells in coculture. The CLL B cells induced IgG production by normal B cells to a similar degree as did purified T cells in a process which was partially inhibited by monoclonal antibody to CD40L. This is one of the first reports of CD40L expression in a B-cell \*\*\*tumor\*\*\*. The data suggest that CD40L in the \*\*\*tumor\*\*\* cells may be a factor in the generation of pathologic antibodies by normal B cells in some patients with CLL.

12/7/30 (Item 30 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

13374833 BIOSIS NO.: 199699008893  
CD20 and CD40 mediated mitogenic responses in B-lineage acute lymphoblastic leukaemia  
AUTHOR: Smiers Frans J; Van Paassen Marleen; Hahlen Karel; Lowenberg Bob; Touw Ivo P (Reprint)  
AUTHOR ADDRESS: Inst. Haematol., Erasmus Univ. Rotterdam, PO Box 1738, 3000 Dr Rotterdam, Netherlands\*\*Netherlands  
JOURNAL: British Journal of Haematology 93 (1): p125-130 1996 1996  
ISSN: 0007-1048  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: Activation of CD20, a cross-membrane ion channel, induces cell cycle progression from G-0 to G-1 in B lymphocytes. Subsequent activation of CD40, a membrane receptor of the nerve growth factor receptor superfamily, transits the B cells to the S phase. CD40 may also act synergistically in combination with IL-4 (B lymphocytes) or IL-3/IL-7 (B-cell precursors). We investigated the proliferative responses of B-lineage acute lymphoblastic leukaemia (ALL) cells to CD20/ \*\*\*CD40\*\*\* activation. In 18/56 ALL cases, \*\*\*CD20\*\*\* activation resulted in significant \*\*\*increases\*\*\* in DNA synthesis. Similar, although more moderate, effects were seen of activation of \*\*\*CD40\*\*\* in 10/44 cases. Responses to CD20 or CD40 activation were independent of co-stimulation with IL-3, IL-4 or IL-7, and various cocktails of the different growth stimuli did not act synergistically.

12/7/42 (Item 7 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0079891356 EMBASE No: 2004076254  
Indolent B-cell malignancies: Immune recognition and antiself  
Gribben J.G.  
Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Avenue, Boston, MA 02115, United States  
AUTHOR EMAIL: john; gribben@dfci.harvard.edu  
CORRESP. AUTHOR/AFFIL: Gribben J.G.: Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Avenue, Boston, MA 02115, United States  
CORRESP. AUTHOR EMAIL: john; gribben@dfci.harvard.edu

Leukemia and Lymphoma ( Leuk. Lymphoma ) (United Kingdom) December 1, 2003, 44/SUPPL. 3 (S77-S83)  
CODEN: LELYE ISSN: 1042-8194

DOI: 10.1080/10428190310001623739

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 56

B-cell malignancies appear to be ideal candidates for treatment with immunotherapeutic approaches. Monoclonal antibodies that target cell-surface determinants have been used as single agents in B-cell malignancies, in combination with chemotherapy, and coupled to other agents to create radioimmunoconjugates and immunotoxins. Another approach is to take advantage of the graft-vs.- \*\*\*lymphoma\*\*\* effect seen following allogeneic bone marrow transplantation. To exploit this effect without inducing the complication of graft-vs.-host disease, it is necessary to understand the mechanisms whereby lymphoma cells escape T-cell-mediated responses. \*\*\*CD40\*\*\* activation may offer a means of increasing the immunogenicity of lymphoma cells and of \*\*\*stimulating\*\*\* allogeneic T-cell proliferation and cytokine production. Vaccination using tumor-specific antigens shows promise as a therapeutic strategy. Pre-clinical studies with immunoglobulin idiotype peptides have shown that humoral and cellular immune responses can be stimulated by antibodies to these peptides, but better tumor antigens need to be identified that can reliably generate cytotoxic T-cell responses. Candidate antigens include heteroclitic peptides from the immunoglobulin V region and newly identified antigens including the cytochrome P450 1B1. Clinical trials are ongoing in all these fields.

12/7/44 (Item 9 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0078325759 EMBASE No: 2000375362

Immunotherapeutic strategies for the treatment of plasma cell malignancies

Treon S.P.; Raje N.; Anderson K.C.

Division of Hematologic Malignancies, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, United States

CORRESP. AUTHOR/AFFIL: Anderson K.C.: Division of Hematologic Malignancies, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, United States

Seminars in Oncology ( Semin. Oncol. ) (United States) November 13, 2000 , 27/5 (598-613)

CODEN: SOLGA ISSN: 0093-7754

DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 156

The use of immunotherapy to treat patients with plasma cell dyscrasias (PCD) such as multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) has gained enormous interest in recent years, with considerable efforts being mounted by many investigators. These efforts have included the use of serotherapy (antibody-mediated immunotherapy), vaccination strategies aimed at inducing allogeneic as well as autologous anti-MM immunity, and the use of donor lymphocyte infusions (DLIs). A number of cell surface antigens on malignant plasma cells and/or B cells in MM and/or WM patients have been proposed for use in tumor cell-targeted serotherapy, including immunoglobulin idiotype, CD19, CD20, CD38, CD54, CD138, HM1.24, and MUC1 core protein. Ongoing clinical trials are examining serotherapy targeting CD20 (in MM and WM) and CD38 (in MM), with early reports of responses to the anti-CD20 monoclonal antibody

(mAb) Rituximab (Genentech, South San Francisco, CA) in patients with WM and certain patients with MM. The use of agents to induce MM- and WM-selective antigens for targeting in serotherapy has been proposed based on studies demonstrating the upregulation of CD20 by interferon-gamma (IFN-gamma), and of MUC1 core protein by dexamethasone (DEX) on malignant plasma cells. Strategies to induce allogeneic anti-MM immunity have included immunization of the marrow donor to idiotypic protein, as well as DLI. In addition, proposed immunization strategies aimed at inducing autologous immunity include vaccination with dendritic cells pulsed with MM antigens, MM cell-dendritic cell fusions, carrier-linked idotype protein, catalytic subunit of telomerase, or DNA encoding for single-chain variable fragments (scFv) linked to a carrier protein gene. Whole \*\*\*tumor\*\*\* vaccination strategies are also being examined and include the use of MM cells transfected and/or stimulated with cytokines, costimulatory molecules, or \*\*\*CD40\*\*\* ligand. Finally, potential obstacles to the use of immunotherapy, including the presence of resistance antigens on MM and WM \*\*\*tumor\*\*\* cells, are discussed. Copyright (C) 2000 by W.B. Saunders Company.

12/7/45 (Item 10 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0078280176 EMBASE No: 2000329766

Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma  
Chaperot L.; Chokri M.; Jacob M.-C.; Drillat P.; Garban F.; Egelhofer H.; Molens J.-P.; Sotto J.-J.; Bensa J.-C.; Plumas J.

Department of Cell Therapy, ETS de l'Isere et de la Savoie, BP 35,  
F-38701 La Tronche Cedex, France  
CORRESP. AUTHOR/AFFIL: Chaperot L.: Department of Cell Therapy, ETS de  
l'Isere et de la Savoie, BP 35, F-38701 La Tronche Cedex, France

Leukemia ( Leukemia ) (United Kingdom) October 2, 2000, 14/9 (1667-1677)  
CODEN: LEUKE ISSN: 0887-6924  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 49

The recent clinical trial in lymphoma using tumor antigen-loaded DCs (Hsu et al, Nature Med 1996; 2: 52) demonstrates the efficiency of the use of professional antigen presenting cells (APCs) for taking up, processing and presenting tumor protein in a vaccine strategy in \*\*\*cancer\*\*\*. However, the production of large quantities of clinical grade APCs remains to be resolved. Here, we describe that both dendritic cells (DCs) and macrophages (M(empty set)s) can be efficiently differentiated in large numbers from lymphoma patients in spite of their disease and previous therapy. These cells were produced using the VAC and MAK cell processors according to standard operating procedures. DCs and M(empty set)s were differentiated from circulating monocytes in gas permeable hydrophobic bags, with 2% autologous serum and in the presence of GM-CSF and IL-13 or GM-CSF alone, respectively. DCs and M(empty set)s were then purified by counter flow centrifugation. Phenotypic, morphological and functional analysis showed that cells differentiated from patients with lymphoma present quite similar features to DCs and M(empty set)s produced from monocytes of healthy donors. Moreover, we show that M(empty set)s, when combined with CD20 antibody (Rituximab), can efficiently engulf tumor cells and propose that a such combination could be used for initiating a clinical trial in \*\*\*lymphoma\*\*\*. Thus, the possibility of producing functional DC and M(empty set)s in large amounts

in conditions compatible with therapeutic application will allow the  
development of new immune strategies to eradicate \*\*\*lymphoma\*\*\* .  
? ds

Set	Items	Description
S1	15	(CD40)(10N)(AGONIST?) AND (CD20 OR RITUXAN OR RITUXIMAB)
S2	9	RD S1 (unique items)
S3	434	(CD40)(10N)(ANTIBOD? OR IMMUNOGLOBULIN?) AND (CD20 OR RITU- XAN OR RITUXIMAB)
S4	280	S3 AND (CANCER? OR TUMOR? OR NEOPLAS? OR TUMOUR? OR LEUKEM- I? OR LYMPHOMA?)
S5	241	RD S4 (unique items)
S6	24	S5 AND (CD40)(20N)(AGONIST? OR STIMULAT? OR INCREAS?)
S7	24	RD S6 (unique items)
S8	0	S (CD40?)(20N)(AGONIST? OR STIMULAT? OR INCREAS?) AND (CD20 OR RITUXAN OR RITUXIMAB)
S9	193	(CD40?)(20N)(AGONIST? OR STIMULAT? OR INCREAS?) AND (CD20 - OR RITUXAN OR RITUXIMAB)
S10	105	RD S9 (unique items)
S11	57	S10 AND(TUMOR? OR TUMOUR? OR CANCER? OR NEOPLAS? OR LEUKEM- I? OR LYMPHOMA?)
S12	57	RD S11 (unique items)
? s ss2c6 and cd40		
	0	SS2C6
	34908	CD40
S13	0	SS2C6 AND CD40
? s s2c6 and cd40		
	31	S2C6
	34908	CD40
S14	17	S2C6 AND CD40
? rd s14		
S15	9	RD S14 (unique items)
? t s15/3/all		

15/3/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18838451 BIOSIS NO.: 200600183846  
The humanized anti-CD40 monoclonal antibody SGN-40 targets Hodgkin's  
disease cells through multiple mechanisms.  
AUTHOR: Law Che-Leung (Reprint); McEarchern Julie A; Cervený Charles G;  
Smith Leia M; Nesterova Albina; Gordon Kristine A; Grewal Iqbal S; Wahl  
Alan F  
AUTHOR ADDRESS: Seattle Genet Inc, Preclin Therapeut, Bothell, WA USA\*\*USA  
JOURNAL: Blood 106 (11, Part 1): p425A-426A NOV 16 2005 2005  
CONFERENCE/MEETING: 47th Annual Meeting of the  
American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005;  
20051210  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

15/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

13260372 BIOSIS NO.: 199698728205

CD40 antibodies defining distinct epitopes display qualitative  
differences in their induction of B-cell differentiation  
AUTHOR: Bjorck P; Paulie S (Reprint)  
AUTHOR ADDRESS: Dep. Immunology, Stockholm Univ., S-106 91 Stockholm,  
Sweden\*\*Sweden  
JOURNAL: Immunology 87 (2): p291-295 1996 1996  
ISSN: 0019-2805  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

15/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

12538024 BIOSIS NO.: 199598005857  
Antibodies to distinct epitopes on the CD40 molecule co-operate in  
stimulation and can be used for the detection of soluble CD40  
AUTHOR: Bjorck P (Reprint); Braesch-Andersen S; Paulie S  
AUTHOR ADDRESS: Dep. Immunol., Stockholm Univ., S-106 91 Stockholm, Sweden  
\*\*Sweden  
JOURNAL: Immunology 83 (3): p430-437 1994 1994  
ISSN: 0019-2805  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

15/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

11899684 BIOSIS NO.: 199396064100  
CD40 plays an essential role in the activation of human B cells by  
murine EL4B5 cells  
AUTHOR: Kwekkeboom J (Reprint); De Boer M; Tager J M; De Groot C  
AUTHOR ADDRESS: Lab. Cell Biol. Histol., Univ. Amsterdam, Acad. Med.  
Center, Meibergdreef 15, 1105 AZ Amsterdam, Netherlands\*\*Netherlands  
JOURNAL: Immunology 79 (3): p439-444 1993  
ISSN: 0019-2805  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

15/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

11394539 BIOSIS NO.: 199294096380  
AGONISTIC PROPERTIES OF ANTI-B CELL ANTIBODIES PURIFIED ON STAPHYLOCOCCAL  
PROTEIN A MAY BE DUE TO CONTAMINATING PROTEIN A  
AUTHOR: JAKOBSON E (Reprint); AXELSSON B; PAULIE S  
AUTHOR ADDRESS: DEP IMMUNOL, S-106 91 STOCKHOLM, SWEDEN\*\*SWEDEN  
JOURNAL: Journal of Immunological Methods 152 (1): p49-57 1992  
ISSN: 0022-1759  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH



15/3/6 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2008 Dialog. All rts. reserv.

08897699 PMID: 2463310

The human B lymphocyte and carcinoma antigen, CDw40, is a phosphoprotein involved in growth signal transduction.

Paulie S; Rosen A; Ehlin-Henriksson B; Braesch-Andersen S; Jakobson E; Koho H; Perlmann P

Department of Immunology, University of Stockholm, Sweden.

Journal of immunology (Baltimore, Md. - 1950) (UNITED STATES) Jan 15 1989, 142 (2) p590-5, ISSN 0022-1767--Print Journal Code: 2985117R

Publishing Model Print

Document type: Journal Article; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

15/3/7 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

144057607 CA: 144(4)57607z PATENT

Combination therapy containing agents for deleting cells expressing CD40 and CD20 antigens

INVENTOR(AUTHOR): Grewal, Iqbal

LOCATION: USA

ASSIGNEE: Genentech, Inc.

PATENT: U.S. Pat. Appl. Publ. ; US 20020197256 A1 DATE: 20021226

APPLICATION: US 200299818 (20020314) \*US 2001PV280805 (20010402)

PAGES: 22 pp. CODEN: USXXCO LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: 424144100; A61K-039/395A

15/3/8 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

143292433 CA: 143(16)292433c PATENT

Conjugates of dolastatin analogs with tumor antigen-binding antibodies for use in tumor therapy

INVENTOR(AUTHOR): Doronina, Svetlana O.; Senter, Peter D.; Toki, Brian E.; Ebens, Allen J.; Kline, Toni Beth; Polakis, Paul; Sliwkowski, Mark X.; Spencer, Susan D.

LOCATION: USA

ASSIGNEE: Seattle Genetics, Inc.

PATENT: PCT International ; WO 200581711 A2 DATE: 20050909

APPLICATION: WO 2004US38392 (20041105) \*US 2003PV518534 (20031106) \*US 2004PV557116 (20040326) \*US 2004PV598899 (20040804) \*US 2004PV622455 (20041027)

PAGES: 426 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;

UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ  
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;  
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LU; MC;  
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;  
MR; NE; SN; TD; TG

15/3/9 (Item 3 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

134041105 CA: 134(4)41105s PATENT  
Recombinant anti-CD40 antibody and uses thereof  
INVENTOR(AUTHOR): Siegall, Clay B.; Wahl, Alan F.; Francisco, Joseph A.;  
Fell, Henry P., Jr  
LOCATION: USA  
ASSIGNEE: Seattle Genetics, Inc.; Fell, Henry P. Jr.  
PATENT: PCT International ; WO 200075348 A1 DATE: 20001214  
APPLICATION: WO 2000US15749 (20000608) \*US 328296 (19990608)  
PAGES: 91 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: C12N-015/63A; C12N-015/00B; G01N-033/53B; A61K-038/00B;  
C07K-005/00B; C07K-014/00B; C07K-016/00B; C07H-021/04B  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA;  
CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU;  
ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD;  
MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM;  
TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ;  
TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT  
; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF;  
BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG  
? s sgn? and cd40  
1838 SGN?  
34908 CD40  
S16 67 SGN? AND CD40  
? rd s16  
S17 45 RD S16 (unique items)  
? s s17 and (antibod? or immunoglobulin)(20n)(sgn?)  
45 S17  
2338190 ANTIBOD?  
694942 IMMUNOGLOBULIN  
1838 SGN?  
168 (ANTIBOD? OR IMMUNOGLOBULIN)(20N)SGN?  
S18 30 S17 AND (ANTIBOD? OR IMMUNOGLOBULIN)(20N)(SGN?)  
? t s18/3/all

18/3/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

0020170675 BIOSIS NO.: 200800217614  
The humanized anti-CD40 monoclonal antibody, SGN-40,  
potentiates chemotherapy regimens in NHL xenograft models via  
pro-apoptotic signaling  
AUTHOR: Lewis Timothy S (Reprint); McCormick Renee S; Kissler Kim; Stone  
Ivan J; Jonas Mechthild; Sutherland May S K; Gerber Hans-Peter; Drachman  
Jonathan G; Grewal Iqbal S; Law Che-Leung  
AUTHOR ADDRESS: Seattle Genet Inc, Bothell, WA USA\*\*USA  
JOURNAL: Blood 110 (11, Part 1): p692A-693A NOV 16 2007 2007  
CONFERENCE/MEETING: 49th Annual Meeting of the  
American-Society-of-Hematology Atlanta, GA, USA December 08 -11, 2007;

20071208  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

0019905925 BIOSIS NO.: 200700565666  
New agents in development for non-Hodgkin's lymphoma  
AUTHOR: Leonard John P (Reprint); Ruan Jia; Martin Peter; Coleman Morton;  
Furman Richard R  
AUTHOR ADDRESS: Weill Cornell Med Coll, Ctr Lymphoma and Myeloma, Starr  
Bldg, Room 340, 520 E 70th St, New York, NY 10021 USA\*\*USA  
AUTHOR E-MAIL ADDRESS: jpleonar@med.cornell.edu  
JOURNAL: Seminars in Hematology 44 (3, Suppl. 4): pS18-S21 JUL 2007 2007  
ITEM IDENTIFIER: doi:10.1053/j.seminhematol.2007.06.005  
ISSN: 0037-1963  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

0019652165 BIOSIS NO.: 200700311906  
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma  
AUTHOR: Fanale Michelle A (Reprint); Younes Anas  
AUTHOR ADDRESS: Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma Myeloma,  
Unit 429, 1515 Holcombe Blvd, Houston, TX 77030 USA\*\*USA  
AUTHOR E-MAIL ADDRESS: mfanale@mdanderson.org  
JOURNAL: Drugs 67 (3): p333-350 2007 2007  
ISSN: 0012-6667  
DOCUMENT TYPE: Article; Literature Review  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

0019600582 BIOSIS NO.: 200700260323  
Results of a phase I trial of SGN-40 (anti-huCD40 mAb) in patients  
with relapsed multiple myeloma.  
AUTHOR: Hussein Mohamad A (Reprint); Berenson James R; Niesvizkyl Ruben;  
Munshi Nikhil C; Matous Jeffrey; Harrop Kate; Drachman Jonathan G  
AUTHOR ADDRESS: Cleveland Clin Fdn, Cleveland, OH 44195 USA\*\*USA  
JOURNAL: Blood 108 (11, Part 1): p1021A NOV 16 2006 2006  
CONFERENCE/MEETING: 48th Annual Meeting of the  
American-Society-of-Hematology Orlando, FL, USA December 09 -12, 2006;  
20061209  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract  
LANGUAGE: English

18/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

0019600512 BIOSIS NO.: 200700260253  
The humanized Anti-CD40 antibody SGN-40 inhibits tumor  
growth in LAG kappa-1A, a CD40(+) mouse model of human multiple  
myeloma.  
AUTHOR: Campbell Richard A (Reprint); Gordon Melinda S; Sanchez Eric; Chen  
Haiming; Turker Lauren; Trac Olivia; Li Mingjie; Pang Shen; Bonavida  
Benjamin; Said Jonathan; Drachman Jonathan G; Berenson James R  
AUTHOR ADDRESS: Inst Myeloma and Bone Canc Res, West Hollywood, CA USA\*\*USA  
JOURNAL: Blood 108 (11, Part 1): p1000A NOV 16 2006 2006  
CONFERENCE/MEETING: 48th Annual Meeting of the  
American-Society-of-Hematology Orlando, FL, USA December 09 -12, 2006;  
20061209  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

0019599508 BIOSIS NO.: 200700259249  
The humanized Anti-CD40 antibody, SGN-40, promotes  
apoptosis signaling and is effective in combination with standard  
therapies in lymphoma xenograft models.  
AUTHOR: Lewis Timothy S (Reprint); Sutherland May S K; Jonas Mechthild;  
Cervený Charles G; McCormick Renee; Wahl Alan F; Drachman Jonathan G;  
Grewal Iqbal S; Law Che-Leung  
AUTHOR ADDRESS: Seattle Genet Inc, Bothell, WA USA\*\*USA  
JOURNAL: Blood 108 (11, Part 1): p708A NOV 16 2006 2006  
CONFERENCE/MEETING: 48th Annual Meeting of the  
American-Society-of-Hematology Orlando, FL, USA December 09 -12, 2006;  
20061209  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/7 (Item 7 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

0019597702 BIOSIS NO.: 200700257443  
SGN-40 (Anti-huCD40 mAb) monotherapy induces durable objective  
responses in patients with relapsed aggressive non-Hodgkin's lymphoma:  
Evidence of antitumor activity from a phase I study.  
AUTHOR: Advani Ranjana (Reprint); Forero-Torres Andres; Furman Richard R;  
Rosenblatt Joseph D; Younes Anas; Shankles Brooke; Harrop Kate; Drachman  
Jonathan G

AUTHOR ADDRESS: Stanford Univ, Med Ctr, Dept Oncol, Stanford, CA 94305 USA  
\*\*USA  
JOURNAL: Blood 108 (11, Part 1): p209A NOV 16 2006 2006  
CONFERENCE/MEETING: 48th Annual Meeting of the  
American-Society-of-Hematology Orlando, FL, USA December 09 -12, 2006;  
20061209  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/8 (Item 8 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

0019553778 BIOSIS NO.: 200700213519  
Preclinical pharmacokinetics, pharmacodynamics and activity of a humanized  
anti-CD40 antibody (SGN-40) in rodents and non-human  
primates (vol 148, pg 1116, 2006)  
AUTHOR: Kelley S K; Gelzleichter T; Xie D; Lee W P; Darbonne W C; Qureshi F  
; Kissler K; Oflazoglu E; Grewal I S  
JOURNAL: British Journal of Pharmacology 150 (2): p248 JAN 2007 2007  
ISSN: 0007-1188  
DOCUMENT TYPE: Article; Errata  
RECORD TYPE: Citation  
LANGUAGE: English

18/3/9 (Item 9 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

19177364 BIOSIS NO.: 200600522759  
Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized  
anti-CD40 antibody (SGN-40) in rodents and non-human  
primates  
AUTHOR: Kelley Sean K; Gelzleichter Thomas; Xie Dong; Lee Wyne P; Darbonne  
Walter C; Qureshi Ferhan; Kissler Kim; Oflazoglu Ezogelin; Grewal Iqbal S  
(Reprint)  
AUTHOR ADDRESS: Seattle Genet Inc, Dept Preclin Therapeut, 21823,30th Dr  
SE, Bothell, WA 98021 USA\*\*USA  
AUTHOR E-MAIL ADDRESS: igrewal@seagen.com  
JOURNAL: British Journal of Pharmacology 148 (8): p1116-1123 AUG 2006 2006  
ISSN: 0007-1188  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/10 (Item 10 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18918280 BIOSIS NO.: 200600263675  
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal  
antibody, SGN-40 (vol 65, pg 8331, 2005)  
AUTHOR: Law C-L; Gordon K A; Collier J; Klussman K; McEarchern J A; Cerveny  
C G; Mixan B J; Lee W P; Lin Z; Valdez P; Wahl A F; Grewal I S  
JOURNAL: Cancer Research 66 (4): p2495 FEB 15 2006 2006

ISSN: 0008-5472  
DOCUMENT TYPE: Article; Errata  
RECORD TYPE: Citation  
LANGUAGE: English

18/3/11 (Item 11 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18839939 BIOSIS NO.: 200600185334  
Humanized anti CD-40 antibody SGN-40 effectively induces  
cytotoxicity against chronic lymphocytic leukemia (CLL) cells through  
antibody mediated cytotoxicity and demonstrates modest biologic  
evidence of CD40 activation  
AUTHOR: Gowda Aruna C (Reprint); Zhao Xiaobin B; Cheney Carolyn; Mehter  
Najma; Lozanski Gerard; Lin Thomas S; Guster Sara; Drachman J G;  
Muthusamy Natarajan; Byrd John C  
AUTHOR ADDRESS: Ohio State Univ, Columbus, OH 43210 USA\*\*USA  
JOURNAL: Blood 106 (11, Part 1): p832A NOV 16 2005 2005  
CONFERENCE/MEETING: 47th Annual Meeting of the  
American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005;  
20051210  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/12 (Item 12 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18839546 BIOSIS NO.: 200600184941  
A phase I humanized Anti-CD40 monoclonal antibody (SGN  
-40) in patients with multiple myeloma.  
AUTHOR: Hussein Mohamad A (Reprint); Berenson James R; Niesvizky Ruben;  
Munshi Nikhil C; Harrop Kate L; McDonald Michael; Drachman Jonathan G  
AUTHOR ADDRESS: Cleveland Clin Taussig Canc Ctr, Cleveland Clin Multiple  
Myeloma Res Program, Cleveland, OH USA\*\*USA  
JOURNAL: Blood 106 (11, Part 1): p723A NOV 16 2005 2005  
CONFERENCE/MEETING: 47th Annual Meeting of the  
American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005;  
20051210  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/13 (Item 13 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18838479 BIOSIS NO.: 200600183874  
A phase I study of humanized anti-CD40 immunotherapy with SGN  
-40 in non-Hodgkin's lymphoma.  
AUTHOR: Advani Ranjana H (Reprint); Furman Richard R; Rosenblatt Joseph D;  
Younes Anas; Forero-Torres Andres; Harrop Kate L; Baumgartner Karen T;

McDonald Michael; Drachman Jonathan G  
AUTHOR ADDRESS: Stanford Univ, Dept Med Oncol, Stanford, CA USA\*\*USA  
JOURNAL: Blood 106 (11, Part 1): p433A NOV 16 2005 2005  
CONFERENCE/MEETING: 47th Annual Meeting of the  
American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005;  
20051210  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/14 (Item 14 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18838451 BIOSIS NO.: 200600183846  
The humanized anti-CD40 monoclonal antibody SGN-40  
targets Hodgkin's disease cells through multiple mechanisms.  
AUTHOR: Law Che-Leung (Reprint); McEarchern Julie A; Cervený Charles G;  
Smith Leia M; Nesterova Albina; Gordon Kristine A; Grewal Iqbal S; Wahl  
Alan F  
AUTHOR ADDRESS: Seattle Genet Inc, Preclin Therapeut, Bothell, WA USA\*\*USA  
JOURNAL: Blood 106 (11, Part 1): p425A-426A NOV 16 2005 2005  
CONFERENCE/MEETING: 47th Annual Meeting of the  
American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005;  
20051210  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/15 (Item 15 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18804047 BIOSIS NO.: 200600149442  
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-  
CD40 SGN-40-induced cytotoxicity in human multiple myeloma:  
Clinical implications  
AUTHOR: Tai Yu-Tzu; Li Xian-Feng; Catley Laurence; Coffey Rory; Breitkreutz  
Iris; Bae Joeeun; Song Weihua; Podar Klaus; Hideshima Teru; Chauhan  
Dharminder; Schlossman Robert; Richardson Paul; Treon Steven P; Grewal  
Iqbal S; Munshi Nikhil C; Anderson Kenneth C (Reprint)  
AUTHOR ADDRESS: Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med  
Oncol, Jerome Lipper Multiple Myeloma Ctr, M557, 44 Binney St, Boston, MA  
02115 USA\*\*USA  
AUTHOR E-MAIL ADDRESS: kennethanderson@dfci.harvard.edu  
JOURNAL: Cancer Research 65 (24): p11712-11720 DEC 15 2005 2005  
ISSN: 0008-5472  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/16 (Item 16 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18618720 BIOSIS NO.: 200510313220  
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal  
antibody, SGN-40  
AUTHOR: Law Che-Leung (Reprint); Gordon Kristine A; Collier John; Klussman  
Kerry; McEarchern Julie A; Cervený Charles G; Mixan Bruce J; Lee Wyne P;  
Lin Zhonghau; Valdez Patricia; Wahl Alan F; Grewal Iqbal S  
AUTHOR ADDRESS: Seattle Genet Inc, 21823 30th Dr SE, Bothell, WA 98021 USA  
\*\*USA  
AUTHOR E-MAIL ADDRESS: claw@seagen.com  
JOURNAL: Cancer Research 65 (18): p8331-8338 SEP 15 2005 2005  
ISSN: 0008-5472  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/17 (Item 17 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18575883 BIOSIS NO.: 200510270383  
A phase I, multi-dose, dose escalation study of SGN-40 (anti-huCD40  
mAb) in patients with refractory or recurrent multiple myeloma  
AUTHOR: Hussein Mohamad A (Reprint); Niesvizky Ruben; Munshi Nikhil;  
Berenson James C; Anderson Kenneth C; Ryan Kate; Baumgartner Karen;  
Miller Dennis M; McDonald Michael  
AUTHOR ADDRESS: Cleveland Clin Multiple Myeloma Res Progam, Taussig Canc  
Ctr, Cleveland, OH USA\*\*USA  
JOURNAL: Blood 104 (11, Part 1): p663A NOV 16 2004 2004  
CONFERENCE/MEETING: 46th Annual Meeting of the  
American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004;  
20041204  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/18 (Item 18 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18574970 BIOSIS NO.: 200510269470  
Enhanced cytotoxicity of monoclonal antibody SGN-40 and  
immunomodulatory drug IMiD3 against human multiple myeloma  
AUTHOR: Tai Yu-Tzu (Reprint); Catley Laurence; Li Xian-Feng; Hamasaki  
Makoto; Podar Klaus; Hideshima Teru; Chauhan Dharminder; Schlossman  
Robert; Richardson Paul; Streon Steven P; Munshi Nikhil C; Anderson  
Kenneth C  
AUTHOR ADDRESS: Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,  
Dept Med Oncol, Boston, MA 02115 USA\*\*USA  
JOURNAL: Blood 104 (11, Part 1): p418A-419A NOV 16 2004 2004  
CONFERENCE/MEETING: 46th Annual Meeting of the  
American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004;  
20041204  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster  
RECORD TYPE: Abstract



LANGUAGE: English

18/3/19 (Item 19 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

17933452 BIOSIS NO.: 200400304209  
Mechanisms by which SGN-40, a humanized anti-CD40  
antibody, induces cytotoxicity in human multiple myeloma cells:  
Clinical implications  
AUTHOR: Tai Yu-Tzu; Catley Laurence P; Mitsiades Constantine S; Burger  
Renate; Podar Klaus; Shringpaure Reshma; Hideshima Teru; Chauhan  
Dharminder; Hamasaki Makoto; Ishitsuka Kenji; Richardson Paul; Treon  
Steven P; Munshi Nikhil C; Anderson Kenneth C (Reprint)  
AUTHOR ADDRESS: Dana Farber Canc InstDept Med Oncol, Jerome Lipper Multiple  
Myeloma Ctr, M557,44 Binney St, Boston, MA, 02115, USA\*\*USA  
AUTHOR E-MAIL ADDRESS: kennethanderson@dfci.harvard.edu  
JOURNAL: Cancer Research 64 (8): p2846-2852 April 15, 2004 2004  
MEDIUM: print  
ISSN: 0008-5472 \_(ISSN print)  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/20 (Item 20 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

17781212 BIOSIS NO.: 200400147873  
Preclinical pharmacokinetics and pharmacodynamics of SGN-40, a  
humanized anti- \*\*\*CD40\*\*\* \*\*\*antibody\*\*\* .  
AUTHOR: Miller Dennis M (Reprint); Kelley Sean; Gelzleichter Tom; Grewal  
Iqbal; Darbonne W C  
AUTHOR ADDRESS: Department of Clinical Affairs, Seattle Genetics, Inc.,  
Bothell, WA, USA\*\*USA  
JOURNAL: Blood 102 (11): p689a November 16, 2003 2003  
MEDIUM: print  
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of  
Hematology San Diego, CA, USA December 06-09, 2003; 20031206  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/21 (Item 21 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

17781045 BIOSIS NO.: 200400147706  
Preclinical antitumor activity of a humanized anti-CD40 monoclonal  
\*\*\*antibody\*\*\* \*\*\*SGN\*\*\* -40.  
AUTHOR: Law Che-Leung (Reprint); Lee Wyne P; Lin Zhonghua; Grewal Iqbal S;  
Wahl Alan (Reprint)  
AUTHOR ADDRESS: Department of Biochemistry, Seattle Genetics, Inc.,  
Bothell, WA, USA\*\*USA  
JOURNAL: Blood 102 (11): p646a November 16, 2003 2003  
MEDIUM: print

CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/22 (Item 22 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

15640053 BIOSIS NO.: 200000358366  
Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14  
AUTHOR: Francisco Joseph A; Donaldson Karen L; Chace Dana; Siegall Clay B; Wahl Alan F (Reprint)  
AUTHOR ADDRESS: Department of Biochemistry, Seattle Genetics, Inc., 22215 26th Avenue SE, Bothell, WA, 98021, USA\*\*USA  
JOURNAL: Cancer Research 60 (12): p3225-3231 June 15, 2000 2000  
MEDIUM: print  
ISSN: 0008-5472  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

18/3/23 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081797759 EMBASE No: 2007231792  
Preliminary phase I evaluations of 2 anti-CD40 monoclonal antibodies in patients with relapsed/refractory multiple myeloma  
Cunningham S.; Muneer S.; Ranganathan A.; Shivakumar L.; Lonial S.; Mughal T.; Armitage J.O.

Clinical Lymphoma and Myeloma ( Clin. Lymphoma Myeloma ) (United States)  
March 1, 2007, 7/5 (342-344)  
ISSN: 1557-9190  
DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Citation  
LANGUAGE: English  
NUMBER OF REFERENCES: 47

18/3/24 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081622101 EMBASE No: 2007055505  
Erratum: Preclinical pharmacokinetics, pharmacodynamics and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates (British Journal of Pharmacology (2006) 148, (1116-1123) DOI: 10.1038/sj.bjp.0706828)  
Kelley S.K.; Gelzleichter T.; Xie D.; Lee W.P.; Darbonne W.C.; Qureshi F.; Kissler K.; Oflazoglu E.; Grewal I.S.

British Journal of Pharmacology ( Br. J. Pharmacol. ) (United Kingdom)  
January 1, 2007, 150/2 (248)  
CODEN: BJPCB ISSN: 0007-1188 eISSN: 1476-5381

PUBLISHER ITEM IDENTIFIER: 0707129  
DOI: 10.1038/sj.bjp.0707129  
DOCUMENT TYPE: Journal; Erratum RECORD TYPE: Citation  
LANGUAGE: English

18/3/25 (Item 3 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081167302 EMBASE No: 2006229528  
5th Annual International Congress on Monoclonal Antibodies in Cancer,  
August 2005, Quebec City, Canada  
Reddy G.K.; Jain V.K.; Nadler E.  
  
Clinical Lymphoma and Myeloma ( Clin. Lymphoma Myeloma ) (United States)  
September 1, 2005, 6/2 (71-76)  
ISSN: 1557-9190  
DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Citation  
LANGUAGE: English  
NUMBER OF REFERENCES: 46

18/3/26 (Item 4 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081037102 EMBASE No: 2006097101  
Erratum: Preclinical antilymphoma activity of a humanized anti-CD40  
monoclonal antibody, SGN-40 (Cancer Research (September 15,  
2005) 65 (8331-8338)

Cancer Research ( Cancer Res. ) (United States) February 15, 2006, 66/4  
(2495)  
CODEN: CNREA ISSN: 0008-5472  
DOI: 10.1158/0008-5472.CAN-66-4-COR  
DOCUMENT TYPE: Journal; Erratum RECORD TYPE: Citation  
LANGUAGE: English  
NUMBER OF REFERENCES: 1

18/3/27 (Item 5 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080618342 EMBASE No: 2005262633  
From Hodgkin disease to Hodgkin lymphoma: Biologic insights and  
therapeutic potential  
Re D.; Thomas R.K.; Behringer K.; Diehl V.  
Burnham Institute, John Reed Laboratory, 10901 N Torrev Pines Rd., San  
Diego, CA 92037, United States  
AUTHOR EMAIL: dre@burnham.org  
CORRESP. AUTHOR/AFFIL: Re D.: Burnham Institute, John Reed Laboratory,  
10901 N Torrev Pines Rd., San Diego, CA 92037, United States  
CORRESP. AUTHOR EMAIL: dre@burnham.org

Blood ( Blood ) (United States) June 15, 2005, 105/12 (4553-4560)  
CODEN: BLOOA ISSN: 0006-4971  
DOI: 10.1182/blood-2004-12-4750  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 100

18/3/28 (Item 6 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080559922 EMBASE No: 2005204182  
Targeting signalling pathways for the treatment of multiple myeloma  
Podar K.; Hideshima T.; Chauhan D.; Anderson K.C.  
Dana-Farber Cancer Institute, Department of Medical Oncology, Harvard  
Medical School, 44 Binney Street, Boston, MA 02115, United States  
AUTHOR EMAIL: klaus; podar@dfci.harvard.edu  
CORRESP. AUTHOR/AFFIL: Podar K.: Dana-Farber Cancer Institute, Department  
of Medical Oncology, Harvard Medical School, 44 Binney Street, Boston, MA  
02115, United States  
CORRESP. AUTHOR EMAIL: klaus; podar@dfci.harvard.edu

Expert Opinion on Therapeutic Targets ( Expert Opin. Ther. Targets ) (   
United Kingdom) April 1, 2005, 9/2 (359-381)  
CODEN: EOTTA ISSN: 1472-8222  
DOI: 10.1517/14728222.9.2.359  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 236

18/3/29 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

146314742 CA: 146(16)314742u JOURNAL  
Preclinical pharmacokinetics, pharmacodynamics, and activity of a  
humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.  
(Erratum to document cited in CA145:290755)  
AUTHOR(S): Kelley, Sean K.; Gelzleichter, Thomas; Xie, Dong; Lee, Wyne P.  
; Darbonne, Walter C.; Qureshi, Ferhan; Kissler, Kim; Oflazoglu, Ezogelin;  
Grewal, Iqbal S.  
LOCATION: Product Portfolio Management, Genentech Inc., South San  
Francisco, CA, USA  
JOURNAL: Br. J. Pharmacol. (British Journal of Pharmacology) DATE: 2007  
VOLUME: 150 NUMBER: 2 PAGES: 248 CODEN: BJPCBM ISSN: 0007-1188  
LANGUAGE: English PUBLISHER: Nature Publishing Group

18/3/30 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

144368130 CA: 144(20)368130v JOURNAL  
preclinical antilymphoma activity of a humanized anti-CD40 monoclonal  
antibody, SGN-40. (Erratum to document cited in CA143:284369)  
AUTHOR(S): Law, Che-Leung; Gordon, Kristine A.; Collier, John; Klussman,  
Kerry; McEarchern, Julie A.; Cervený, Charles G.; Mixan, Bruce J.; Lee,  
Wyne P.; Lin, Zhonghau; Valdez, Patricia; Wahl, Alan F.; Grewal, Iqbal S.  
LOCATION: Seattle Genetics, Inc., Bothell, WA, USA  
JOURNAL: Cancer Res. (Cancer Research) DATE: 2006 VOLUME: 66 NUMBER: 4  
PAGES: 2495 CODEN: CNREA8 ISSN: 0008-5472 LANGUAGE: English  
PUBLISHER: American Association for Cancer Research  
? t s18/7/19,22

18/7/19 (Item 19 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

17933452 BIOSIS NO.: 200400304209

Mechanisms by which SGN-40, a humanized anti-CD40  
antibody, induces cytotoxicity in human multiple myeloma cells:  
Clinical implications

AUTHOR: Tai Yu-Tzu; Catley Laurence P; Mitsiades Constantine S; Burger  
Renate; Podar Klaus; Shringpaure Reshma; Hideshima Teru; Chauhan  
Dharminder; Hamasaki Makoto; Ishitsuka Kenji; Richardson Paul; Treon  
Steven P; Munshi Nikhil C; Anderson Kenneth C (Reprint)

AUTHOR ADDRESS: Dana Farber Canc InstDept Med Oncol, Jerome Lipper Multiple  
Myeloma Ctr, M557,44 Binney St, Boston, MA, 02115, USA\*\*USA

AUTHOR E-MAIL ADDRESS: kennethanderson@dfci.harvard.edu

JOURNAL: Cancer Research 64 (8): p2846-2852 April 15, 2004 2004

MEDIUM: print

ISSN: 0008-5472 \_(ISSN print)

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: CD40 is expressed on B-cell malignancies, including human  
multiple myeloma (MM) and a variety of carcinomas. We examined the  
potential therapeutic utility of SGN-40, the humanized anti-  
CD40 monoclonal antibody, for treating human MM using MM cell  
lines and patient MM cells (CD138++, \*\*\*CD40\*\*\* +). \*\*\*SGN\*\*\* -40 (0.01-100  
µg/ml) induces modest cytotoxicity in MM cell lines and patient MM  
cells. In the presence of de novo protein synthesis inhibitor  
cycloheximide, SGN-40 significantly induced apoptosis in  
Dexamethasone (Dex)-sensitive MM.1S and Dex-resistant MM.1R cells and in  
patient MM cells. \*\*\*SGN\*\*\* -40-mediated cytotoxicity is associated with  
up-regulation of cytotoxic ligands of the tumor necrosis factor family  
(Fas/FasL, tumor necrosis factor-related apoptosis-inducing ligand, and  
tumor necrosis factor α). \*\*\*SGN\*\*\* -40 treatment also induces a  
down-regulation of \*\*\*CD40\*\*\* dependent on an endocytic pathway.  
Consequently, pretreatment of MM cells with SGN-40 blocked  
sCD40L-mediated phosphatidylinositol 3'-kinase/AKT and nuclear factor  
κappaB activation. Importantly, pretreatment of MM.1S and MM.1R cells  
with SGN-40 inhibited proliferation triggered by interleukin 6  
(IL-6) but not by insulin-like growth factor-I. In addition, \*\*\*SGN\*\*\* -40  
pretreatment of MM.1S cells blocked the ability of IL-6 to protect  
against Dex-induced inhibition of DNA synthesis. This was associated with  
a 2-4-fold reduction of IL-6 receptor at protein and mRNA levels in  
\*\*\*SGN\*\*\* -40-treated MM.1S cells and patient MM cells. Taken together,  
these results provide the preclinical rationale for the evaluation of  
\*\*\*SGN\*\*\* -40 as a potential new therapy to improve patient outcome in MM.

18/7/22 (Item 22 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

15640053 BIOSIS NO.: 200000358366

Agonistic properties and in vivo antitumor activity of the anti-CD40  
antibody SGN-14

AUTHOR: Francisco Joseph A; Donaldson Karen L; Chace Dana; Siegall Clay B;  
Wahl Alan F (Reprint)

AUTHOR ADDRESS: Department of Biochemistry, Seattle Genetics, Inc., 22215  
26th Avenue SE, Bothell, WA, 98021, USA\*\*USA

JOURNAL: Cancer Research 60 (12): p3225-3231 June 15, 2000 2000

MEDIUM: print  
ISSN: 0008-5472  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: Ligation of CD40 is essential for primary B-cell activation and expansion and yet has suppressive or apoptotic effects on some \*\*\*CD40\*\*\* -expressing neoplasia. \*\*\*SGN\*\*\* -14 is a monoclonal \*\*\*antibody\*\*\* that binds to the human \*\*\*CD40\*\*\* receptor. Here we report that SGN-14, in the presence of interleukin 4, provided a modest level of stimulation of peripheral blood B cells, as measured by proliferation. Stimulation was greatly enhanced in the presence of nonproliferating \*\*\*CD40\*\*\* ligand-expressing cells. The enhanced agonistic activity could be attributed to a dose-dependent increase in CD40L binding to \*\*\*CD40\*\*\* in the presence of \*\*\*SGN\*\*\* -14. In contrast to its proliferative effect on primary B cells, SGN-14 inhibited the growth of B-cell-derived tumor lines in vitro, and this growth inhibition was enhanced in the presence of CD40L-expressing cells. In vivo, SGN-14 showed significant antitumor activity in treating human B-cell lymphoma and multiple myeloma xenografted severe combined immunodeficient mice. Antitumor activity was not diminished by blunting murine natural killer activity, suggesting that CD40 ligation contributes to the antitumor efficacy of \*\*\*SGN\*\*\* -14. On the basis of these activities, SGN-14 is being pursued for therapeutic use in treating patients with \*\*\*CD40\*\*\* -expressing hematological malignancies.

? ds

Set	Items	Description
S1	15	(CD40)(10N)(AGONIST?) AND (CD20 OR RITUXAN OR RITUXIMAB)
S2	9	RD S1 (unique items)
S3	434	(CD40)(10N)(ANTIBOD? OR IMMUNOGLOBULIN?) AND (CD20 OR RITUXAN OR RITUXIMAB)
S4	280	S3 AND (CANCER? OR TUMOR? OR NEOPLAS? OR TUMOUR? OR LEUKEM- I? OR LYMPHOMA?)
S5	241	RD S4 (unique items)
S6	24	S5 AND (CD40)(20N)(AGONIST? OR STIMULAT? OR INCREAS?)
S7	24	RD S6 (unique items)
S8	0	S (CD40?)(20N)(AGONIST? OR STIMULAT? OR INCREAS?) AND (CD20 OR RITUXAN OR RITUXIMAB)
S9	193	(CD40?)(20N)(AGONIST? OR STIMULAT? OR INCREAS?) AND (CD20 - OR RITUXAN OR RITUXIMAB)
S10	105	RD S9 (unique items)
S11	57	S10 AND(TUMOR? OR TUMOUR? OR CANCER? OR NEOPLAS? OR LEUKEM- I? OR LYMPHOMA?)
S12	57	RD S11 (unique items)
S13	0	SS2C6 AND CD40
S14	17	S2C6 AND CD40
S15	9	RD S14 (unique items)
S16	67	SGN? AND CD40
S17	45	RD S16 (unique items)
S18	30	S17 AND (ANTIBOD? OR IMMUNOGLOBULIN)(20N)(SGN?)
		?